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A B S T R A C T
Background
Epilepsy is a common neurological disorder. In approximately 30% of epilepsy cases, seizures are uncontrolled by one antiepileptic
drug (AED). These people require treatment with a combination of multiple AEDs and are described as having drug-resistant epilepsy.
Oxcarbazepine is a keto-analogue of carbamazepine, an established AED, and can be used as an add-on treatment for drug-resistant
epilepsy.
Objectives
To assess the eIicacy and tolerability of oxcarbazepine as an add-on treatment for people with drug-resistant focal epilepsy.
Search methods
The following databases were searched on 24 September 2018: Cochrane Register of Studies (CRS Web), which includes the Cochrane
Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); Medline (Ovid) 1946 to 21 September
2018; ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). Originally, we also
searched SCOPUS as a substitute for Embase, but this is no longer necessary, because randomised and quasi-randomised controlled trials
in Embase are now included in CENTRAL.
Selection criteria
Randomised controlled trials with parallel-group or cross-over design, recruiting people of any age with drug-resistant focal epilepsy. We
accepted any level of blinding and trials could be placebo- or active-controlled.
Data collection and analysis
In accordance with the methodological procedures expected by the Cochrane Collaboration, two review authors independently assessed
trial eligibility before extracting data and assessing risk of bias. We assessed the primary outcomes: median percentage seizure reduction
per 28 days; 50% or greater reduction in seizure frequency; and adverse eIects including ataxia, hyponatraemia, and somnolence. We
assessed the secondary outcomes: seizure freedom; treatment withdrawal; cognitive eIects; and quality of life. We used an intention-to-
treat population for all primary analyses. We present results as risk ratios (RR) with 95% confidence intervals (CI), with the exception of
adverse eIects which we present with 99% CI.
Main results
We identified six eligible studies, involving 1593 participants. We judged that three studies were at unclear risk of bias and three were at
high risk of bias. Bias mainly arose from lack of methodological details and from high attrition rates. Participants were aged 1 month to 65
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years, with a diagnosis of drug-resistant focal epilepsy. All studies were either placebo- or alternative-dose-controlled with parallel-group
design. The treatment period varied from 9 days to 26 weeks.
The median percentage seizure reduction per 28 days (3 studies; moderate-certainty evidence) ranged from 26% to 83.3% for participants
randomised to experimental oxcarbazepine compared to 7.6% to 28.7% for participants randomised to control treatment. Oxcarbazepine
may increase the responder rate for 50% or greater reduction in seizure frequency compared to control treatment (RR 1.80, 95% CI 1.27 to
2.56; random-eIects model; 6 studies; low-certainty evidence). For seizure freedom, the RR was 2.86 (95% CI 1.19 to 6.87; random-eIects
model; 5 studies; low-certainty evidence), suggesting an advantageous eIectiveness of oxcarbazepine over control treatment. Treatment
with oxcarbazepine was associated with an increased treatment withdrawal rate compared to control (RR 1.75, 95% CI 1.44 to 2.13; fixed-
eIect model; 6 studies; moderate-certainty evidence). The largest oxcarbazepine dose used, 2400 mg/d, was associated with a higher
treatment withdrawal rate (RR 2.38, 95% CI 1.92 to 2.94; fixed-eIect model; 2 studies) compared to control, than 1200 mg/d (RR 1.54, 95% CI
1.21 to 1.95; fixed-eIect model; 3 studies) or 600 mg/d oxcarbazepine (RR 0.79, 95% CI 0.55 to 1.15; fixed-eIect model; 1 study). Treatment
with oxcarbazepine was associated with an increased incidence of multiple adverse eIects including: ataxia (RR 2.54, 99% CI 0.86 to 7.54;
random-eIects model; 5 studies; moderate-certainty evidence); and somnolence (RR 2.03, 99% CI 1.17 to 3.54; random-eIects model; 6
studies; low-certainty evidence). Hyponatraemia occurred more frequently with oxcarbazepine treatment but not significantly so (RR 2.53,
99% CI 0.27 to 23.85; fixed-eIect model; 6 studies; moderate-certainty evidence).
Authors' conclusions
Oxcarbazepine might be eIective at reducing seizure frequency when used as an add-on for drug-resistant focal epilepsy. The eIicacy
outcomes — 50% or greater seizure reduction and seizure freedom — were derived from low-certainty evidence. We are, therefore,
uncertain whether the estimated eIect size is representative of the true eIect. In contrast, the evidence for median percentage seizure
reduction and treatment withdrawal were of moderate certainty: thus, we are fairly certain of the eIect estimates' reliability. Overall, we
are unsure of the true eIicacy of oxcarbazepine, but have concerns about its tolerability.
P L A I N   L A N G U A G E   S U M M A R Y
Oxcarbazepine add-on for drug-resistant focal epilepsy
Background
Epilepsy is a neurological disorder which causes people to have seizures. Most people can control their epilepsy with a single antiepileptic
drug. Some people, however, require multiple antiepileptic drugs to control their epilepsy, and are said to have drug-resistant epilepsy.
Oxcarbazepine is an antiepileptic drug and is similar to an older antiepileptic drug, carbamazepine. Oxcarbazepine can be taken as an add-
on treatment, alongside other antiepileptic medication, to treat drug-resistant epilepsy.
Aim of the review
This review examined whether oxcarbazepine is tolerable and eIective when used alongside other antiepileptic medication by people with
drug-resistant focal epilepsy (epilepsy that originates from one area of the brain).
Results
We included six clinical trials that investigated oxcarbazepine as an add-on treatment for people with drug-resistant focal epilepsy. There
were 1593 people across the studies and they were aged from 1 month to 65 years.
People who received oxcarbazepine in addition to their normal antiepileptic medication were more likely to have a 50% or greater
reduction in the frequency of their seizures compared to people who were on a control treatment, which is believed to have little or no
eIect. They were also nearly three times more likely to be free from all seizures than those receiving control treatment. Both of these
findings suggest that oxcarbazepine is eIective at treating drug-resistant focal epilepsy. These findings are, however, based on evidence
that was of low certainty. This means that we are not confident that the findings that we have reported are accurate.
People who received oxcarbazepine add-on treatment were also more likely to withdraw from the studies and were more likely to
experience side eIects, including dizziness and drowsiness, than people receiving control add-on treatment. The evidence for treatment
withdrawal was of moderate certainty, and this means that we can be fairly confident that this is a true eIect.
Authors' conclusions
As a result of the low-certainty evidence, we cannot be sure that oxcarbazepine is an eIective add-on treatment for people with drug-
resistant focal epilepsy. Instead, we have concerns about the tolerability of oxcarbazepine because of the increased number of people who
withdrew from treatment and who experienced side eIects.
The evidence is current to September 2018.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Oxcarbazepine compared to control for drug-resistant focal epilepsy
Oxcarbazepine compared to control for drug-resistant focal epilepsy
Patient or population: drug-resistant focal epilepsy
Setting: outpatients (except for 1 study which was conducted in a hospital setting to allow EEG-recording)
Intervention: Oxcarbazepine (600 mg/d, 1200 mg/d, 2400 mg/d, 10 mg/kg/d, and 60 mg/kg/d)
Comparison: control (placebo or alternative lower dose of oxcarbazepine)
Anticipated absolute effects* (95% CI)Outcomes



















Follow-up: 9 days to 26
weeks
The values reported ranged from 7.6% to 28.7% seizure re-
duction with 2 of the 3 studies specifically reporting percent-
age reductions of less than 10%. The median percentage
seizure reduction for participants randomised to experimen-
tal oxcarbazepine treatment ranged from 26% to 83.3%. Im-
portantly, for each study that described this outcome, the
median percentage seizure reduction reported was consis-
tently higher in experimental oxcarbazepine treatment group






creases the median per-
centage seizure reduction
per 28 days attained by
participants.
Study population50% or greater reduc-
tion in seizure frequen-
cy
Follow-up: 9 days to 26
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ticipants achieving a 50%
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Follow-up: 9 days to 26
weeks
0 per 558 5 per 1035
Study populationSomnolence
Follow-up: 9 days to 26
weeks









crease the incidence of
somnolence but we are
uncertain.
Study populationSeizure freedom
Follow-up: 9 days to 26
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seizure freedom amongst
participants but we are
uncertain.
Study populationTreatment withdrawal
Follow-up: 9 days to 26
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*The risk in the intervention group (and its 95% CI for efficacy outcomes, including treatment withdrawal, and 99% CI for adverse effects) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI for efficacy outcomes, including treatment withdrawal, and 99% CI for adverse effects).
# For the adverse event, Hyponatraemia, we have reported the Number of events recorded per number of randomised participants rather than the Anticipated ab-
solute effects. Under the circumstances, this measure was considered more informative.
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
aEvidence downgraded once for risk of bias: 3 of the studies had unclear risk of bias and 3 studies had high risk of bias. This was largely due to studies not specifying their methods
for randomisation and allocation concealment, as well as due to high attrition rates noted in some studies.
b Evidence downgraded once due to inconsistency: significant heterogeneity between studies detected.
cEvidence downgraded once due to imprecision: wide confidence intervals and sub-optimal number of events included in analysis.
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B A C K G R O U N D
Description of the condition
Epilepsy is a disease arising from an enduring and pathological
excessive discharge of a set of neurons in the brain, clinically
characterised by recurrent unprovoked epileptic seizures or in the
context of an epilepsy syndrome. There are many causes alongside
several clinical and electroencephalographic manifestations that
can result in epilepsy (Fisher 2014). The condition is associated with
considerable physical, cognitive, psychiatric and psychological co-
morbidity (LaFrance 2008; Burton 2012).
Epilepsy is common worldwide. A meta-analysis of 65 studies
estimated lifetime prevalence in high-income countries as 5.8 per
1000; whereas in resource-poor countries the estimate was 10.3 per
1000 in urban areas, and in rural areas the estimate was 15.4 per
1000 (Bell 2014).
The United Kingdom General Practice Study of Epilepsy found
60% of epilepsies to be convulsive, of which around two-
thirds comprised focal seizures or focal seizures with secondary
generalisation (Sander 1990; Shorvon 2014). Epilepsy is commonly
treated with antiepileptic drugs (AEDs), with many patients
rendered seizure-free. Unfortunately, an estimated 30% of epilepsy
cases are resistant to conventional AED regimens and can require
several agents to control seizures (Cockerell 1995; Kwan 2000). This
is especially prevalent with focal seizures which originate from one
area of the brain. Drug-resistant epilepsy is defined as "failure of
adequate trials of two tolerated and appropriately chosen and used
AED schedules (whether as monotherapies or in combination) to
achieve sustained seizure freedom" (ILAE 2009). There are also non-
medical interventions available for epilepsy, such as vagal nerve
stimulation or surgery (Panebianco 2015; West 2019).
Description of the intervention
Oxcarbazepine is an analogue of carbamazepine. Oxcarbazepine
is thought to have certain advantages over carbamazepine.
In particular, there are fewer side eIects associated with
oxcarbazepine and the dose can be titrated to a therapeutic
dose more quickly (Grant 1992). Oxcarbazepine is an AED used as
monotherapy for children and adults with focal-onset seizures. It
is established as an eIicacious initial monotherapy in children and
as a potentially eIicacious initial monotherapy for adults (Glauser
2013).
How the intervention might work
AEDs have numerous modes of action. Generally, they inhibit
generation of seizure discharge by communicating with several
molecular targets in the brain to reduce neuronal excitation or
increase inhibition (Porter 2018). Oxcarbazepine has been shown
to exert antiepileptic activity by blockade of voltage-dependent
sodium channels in the brain. Based on in vitro and in vivo findings
and compared with antiepileptic drugs such as carbamazepine,
phenytoin and phenobarbital, oxcarbazepine has a low propensity
for drug‒drug interactions (Flesch 2004). Oxcarbazepine is,
however, metabolised hepatically and is rapidly reduced by
cytosolic enzymes in the liver to its monohydroxy derivative (MHD),
which is responsible for the pharmacological eIect of the drug.
Oxcarbazepine could, therefore, potentiate other AEDs that are
metabolised hepatically. At oxcarbazepine doses above 1.2 g, a 40%
increase in the concentration of phenytoin and a 15% increase in
phenobarbital levels are observed. Furthermore, oxcarbazepine is
associated with decreased clearance with moderate to severe renal
impairment. Dose adjustments are thus necessary in situations of
AED polypharmacy and in instances of moderate to severe renal
impairment (Flesch 2004).
Why it is important to do this review
A large amount of evidence has been accrued regarding the eIicacy
and tolerability of new AEDs. The International League Against
Epilepsy and other organisations have produced guidelines on
how to select new AEDs (UK Oxcarbazepine Advisory Board 2001;
Kang 2012). New AEDs have been tested and used with success,
mainly as add-on therapies to standard drugs such as phenytoin,
carbamazepine and valproate. The majority of trials investigating
add-on therapy with AEDs have recruited patients with focal
epilepsy (experiencing simple focal and/or complex focal and/or
secondary generalised tonic-clonic seizures; ILAE 1989) that have
been resistant to antiepileptic drug treatment.
The introduction of several new AEDs means that systematic
reviews are needed to determine their eIect as add-on agents for
people with focal seizures. These reviews will help inform clinicians
on the best add-on agents to use for their patients (Marson 1997;
Privitera 1999). We therefore present a systematic review focusing
on the eIects of oxcarbazepine on seizures, side eIects, cognition
and quality of life when used as an add-on treatment for patients
with drug-resistant focal epilepsy.
O B J E C T I V E S
To assess the eIicacy and tolerability of oxcarbazepine as an add-
on treatment for people with drug-resistant focal epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To be included in the review, we required studies to meet the
following criteria.
1. Randomised controlled trials (RCTs), including quasi-
randomised trials.
2. Double, single or unblinded trials.
3. Placebo-controlled or active-controlled studies.
4. Parallel group or cross-over studies. For cross-over studies, we
planned to use the first treatment period as a parallel trial.
Types of participants
Adults and children with drug-resistant focal epilepsy, as defined
by the International League Against Epilepsy (ILAE 2009). We
included participants who had undergone other interventions to
treat epilepsy, such as surgery, vagal nerve stimulation or ketogenic
diet.
Types of interventions
1. The active treatment group received therapy with
oxcarbazepine, in addition to their usual treatment.
2. The control group received placebo, an alternative antiepileptic
drug or a diIerent dose of oxcarbazepine, in addition to their
usual treatment.
Oxcarbazepine add-on for drug-resistant focal epilepsy (Review)
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Types of outcome measures
Primary outcomes
(1) Median percentage seizure reduction per 28 days
The median percentage seizure reduction every four weeks in the
treatment period compared to the pre-randomisation baseline
period.
(2) 50% or greater reduction in seizure frequency
The proportion of participants with a 50% or greater reduction in
seizure frequency in the treatment period compared to the pre-
randomisation baseline period.
(3) Adverse e8ects




















19.Any other adverse eIect
Secondary outcomes
(1) Seizure freedom
The proportion of participants who had complete cessation of
seizures during the treatment period.
(2) Treatment withdrawal
We chose the proportion of participants who withdrew from the
treatment during the course of the treatment period as a 'global
measure of tolerability'. In studies of relatively short duration,
treatment is unlikely to be withdrawn due to lack of eIicacy and
any treatment withdrawal is likely due to side eIects.
(3) Cognitive e8ects
At present, there is no consensus as to which instruments should
be used to assess the eIects of AEDs on cognition. As a result, we
approached the assessment of cognitive eIects in a heterogeneous
way (Cochrane 1998).
(4) Quality of life
Once again, there is no consensus as to which instruments
should be used to assess this and we expected to see significant
heterogeneity in the outcome measures used.
Search methods for identification of studies
Electronic searches
We ran the first searches for this review in July 2014. We ran
subsequent searches in December 2016; and we ran the most recent
searches on 24 September 2018, when we searched the following
databases. There were no language restrictions.
1. Cochrane Register of Studies (CRS Web), which includes the
Cochrane Epilepsy Group Specialized Register and the Cochrane
Central Register of Controlled Trials (CENTRAL), using the search
strategy set out in Appendix 1.
2. MEDLINE (Ovid) 1946 to 21 September 2018 using the search
strategy set out in Appendix 2.
3. ClinicalTrials.gov using the search strategy set out in Appendix 3.
4. WHO International Clinical Trials Registry Platform (ICTRP) using
the search strategy set out in Appendix 4.
Previously SCOPUS was searched as an alternative to Embase
but this is no longer necessary, because randomised and quasi-
randomised controlled trials in Embase are now included in
CENTRAL.
Searching other resources
References from published studies
We reviewed the reference lists of retrieved studies to search for
additional reports of relevant studies.
Eorts to identify unpublished studies
We sought unpublished data from Novartis (the manufacturer of
oxcarbazepine); we were unable to obtain any, however.
Other
We asked colleagues if they were aware of any studies that we may
have missed.
Data collection and analysis
Selection of studies
Two review authors (RB and MO) independently assessed the
titles and abstracts identified from the searches and excluded any
irrelevant studies. The same two authors then reviewed the full-text
papers for inclusion. We resolved any disagreements by discussion;
or, if necessary, by asking the third author (AGM) to arbitrate.
Data extraction and management
The review authors extracted the following information from
included trials. Again, we resolved any disagreements by
discussion.
Methodological trial design
1. Method of concealing randomisation.
2. Method of blinding.
Oxcarbazepine add-on for drug-resistant focal epilepsy (Review)
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3. Whether any participants had been excluded from reported
analyses.
4. Duration of baseline period.
5. Duration of treatment period.
6. Dose(s) of oxcarbazepine tested and potential comparator AED
treatment type and dose.
Patient/demographic information
1. Number of participants allocated to each treatment group.
2. Age/sex.
3. Seizure types.
4. Seizure frequency during baseline period.
5. Number of background drugs.
Where necessary, we asked original authors to confirm:
1. the method of randomisation;
2. the total number of participants randomised to each group;
3. the number of participants in each group achieving a 50% or
greater reduction in seizure frequency per treatment group;
4. the number of participants having treatment withdrawn post
randomisation per treatment group.
And for those excluded:
1. the reason for exclusion;
2. whether any of those excluded completed the treatment phase;
3. whether any of those excluded had a 50% or greater reduction
in seizure frequency during the treatment phase.
Outcomes
We recorded the number of participants experiencing each
outcome per randomised group (see Types of outcome measures).
Assessment of risk of bias in included studies
Two review authors (RB, MO) independently assessed the risk of
bias for each trial in accordance with the Cochrane 'Risk of bias'
tool, as described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We discussed any disagreements
and, if necessary, sought the opinion of a third review author
(AGM). Studies were rated as having a high, low or unclear
risk of bias for six domains applicable to RCTs: randomisation
sequence; allocation concealment; blinding; incomplete data
outcome; selective outcome reporting; and other sources of bias.
We also assessed the potential impact of outcome reporting bias by
including an Outcome Reporting Bias in Trials (ORBIT) table in the
review (Kirkham 2010).
Measures of treatment e8ect
For dichotomous outcomes, such as seizure reduction, seizure
freedom, and treatment withdrawal we reported risk ratios (RRs)
using 95% confidence intervals. We presented the proportion of
participants reporting individual adverse eIects as an RR but using
99% confidence intervals in an attempt to compensate for multiple
outcome testing.
For continuous outcomes — such as cognitive eIects and quality of
life — in a meta-analysis, we had ideally planned to report the mean
diIerence. Only one study reported either of these outcomes: it was
not necessary or possible, therefore, to complete a meta-analysis.
Unit of analysis issues
We did not include any cross-over studies in the review; therefore
we did not encounter any unit of analysis issues in this regard, and
did not require any compensatory methods.
For trials with more than one treatment arm (for example, diIerent
doses of oxcarbazepine versus a control group), we combined the
treatment groups for the main meta-analysis and then investigated
the dosage eIects separately during subgroup analysis.
Dealing with missing data
In the event of missing data, we sought reasons for this by
contacting study authors in order to conclude whether data were
missing at random or not.
Assessment of heterogeneity
Two authors (RB, MO) independently assessed clinical and
methodological heterogeneity. Although we detected some
diIerences in control groups, outcome measures and time
scales, we did not detect significant clinical or methodological
heterogeneity to the degree to which meta-analysis would be
inappropriate.
We visually assessed the clinical and methodological heterogeneity
of the included studies. We used the I2 statistic and a Chi2 test,
where applicable, to assess statistical heterogeneity. We judged a
Chi2 P value of less than 0.10 or I2 greater than 50% to indicate
statistical heterogeneity.
Assessment of reporting biases
We requested protocols from study authors and investigated
outcome reporting bias using the ORBIT matrix system (Kirkham
2010).
To examine publication bias, we searched for unpublished data
by carrying out a comprehensive search of multiple sources
and requested any unpublished data from study authors. We
also looked for small-study eIects to establish the likelihood of
publication bias.
Data synthesis
We combined data in a fixed-eIect meta-analysis. Where there
was significant clinical, methodological or statistical heterogeneity,
however, we combined data in a random-eIects meta-analysis.
Subgroup analysis and investigation of heterogeneity
Where possible, we stratified subgroup analysis by type of control
group, age group (adults or children), duration of treatment, and
experimental treatment dose.
Sensitivity analysis
We did not conduct any sensitivity analyses as part of this review.
Summary of findings and assessment of the certainty of the
evidence
We (RB, MO) used the GRADE approach to interpret findings and to
assess the certainty of evidence used in the review (Schunemann
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2011). We used GRADE Profiler SoSware (GRADEPro GDT 2015);
and imported data from Review Manager 5 (RevMan 5) to create a
'Summary of findings' table for the main comparison in the review:
oxcarbazepine versus control, including the primary and secondary
outcomes (see Summary of findings for the main comparison;
Review Manager 2014). We evaluated the evidence across eight
criteria (risk of bias; inconsistency; indirectness; imprecision;
publication bias; eIect size; presence of plausible confounding
factors; and dose-response gradient), according to the GRADE
approach, to determine the certainty of evidence. The 'Summary
of findings' table thus includes information on overall certainty
of the evidence from the trials and information of importance for
healthcare decision making.
R E S U L T S
Description of studies
Results of the search
The search identified 592 records for potential inclusion; and we
found one additional record through other sources (Figure 1).
We contacted Novartis for additional unpublished data, including
any unpublished studies that we may not have been aware
of. Unfortunately, we received no correspondence. We removed
125 duplicate records; followed by a further 368 records due to
irrelevance. We then screened the remaining 100 records to assess
their eligibility for inclusion, according to the information provided
in the title and abstract of each record. Next, we attempted to
retrieve the full texts for the 38 records that remained aSer the
initial screening for the full-text screening stage. We assessed
that 20 records remained eligible for inclusion following the
two screening exercises. The 20 records related to six individual
trials (Barcs 2000; Glauser 2000; Kraiprab 2005; Pina-Garza 2005;
NCT00975715; French 2014). We extracted the data from these six
studies and included them in the subsequent meta-analysis.
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Figure 1.   Study flow diagram. OXC: Oxcarbazepine
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Figure 1.   (Continued)
 
Included studies
The six included studies were all randomised, controlled trials
with parallel group design (Barcs 2000; French 2014; Glauser
2000; Kraiprab 2005; Pina-Garza 2005; NCT00975715). Four of the
included studies were placebo-controlled (Barcs 2000; Glauser
2000; French 2014; NCT00975715); whilst two of the studies were
alternative-dose-controlled (Kraiprab 2005; Pina-Garza 2005). All of
the included studies, with the exception of one — Kraiprab 2005 —
were multi-centre studies; and all but one study — Pina-Garza 2005
— were double-blind. Pina-Garza 2005 was instead rater-blind. We
provide specific details regarding the demographic of the individual
treatment groups for each study in the Characteristics of included
studies tables.
Barcs 2000 was a multi-centre, placebo-controlled, double-
blind study, conducted across 11 countries in 73 centres.
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Eligible participants were aged 15 to 65 and had drug-resistant
focal epilepsy. Focal seizures could be simple or complex in
nature, with or without secondary generalisation. The study
consisted of a prospective baseline period, following which
participants were randomised to one of four treatment groups:
600 mg/d oxcarbazepine; 1200 mg/d oxcarbazepine; 2400 mg/
d oxcarbazepine; or placebo. ASer randomisation, participants
entered a 2-week up-titration period followed by a 24-week
maintenance period. Following completion of the trial, there was
the option for participants to enter an open-label extension study.
French 2014 was similarly a multi-centre, placebo-controlled,
double-blind study. Eighty-eight sites were involved in the study
and they were located across eight countries: USA, Mexico, Canada,
Russia, Poland, Bulgaria, Croatia, and Romania. Participants were
aged 18 to 65 and all participants had drug-resistant focal
epilepsy, characterised by uncontrolled focal-onset seizures, with
or without secondary generalisation. The majority of participants
were taking two concomitant AEDs during their involvement in the
study. Again, this study included an 8-week prospective baseline
period that preceded participant randomisation. Participants
were randomised to one of three treatment groups: 1200
mg/d oxcarbazepine; 2400 mg/d oxcarbazepine; or placebo.
ASer randomisation, participants underwent a 4-week up-
titration period followed by a 12-week maintenance period. ASer
completing the trial, participants chose whether to enter a 3-week
conversion period which led into an open-label extension study; or
whether to undergo a tapering period to return to their baseline
therapy.
Glauser 2000 was also a multi-centre, placebo-controlled, double-
blind study. The trial included 47 sites, distributed across eight
countries: Argentina, Chile, Uruguay, Australia, New Zealand,
Canada, Israel, and USA. In contrast to the other studies, Glauser
2000 only included participants aged 3 to 17 years and thus
focused on the eIicacy of oxcarbazepine in children. Again,
participants were required to have drug-resistant focal epilepsy,
despite receiving one or two concomitant AEDs. Following an 8-
week prospective baseline period, participants were randomised
to one of two treatment groups: 30 to 46 mg/kg/d oxcarbazepine
or placebo. ASer being randomised, participants underwent a 2-
week titration period before entering into a 14-week maintenance
period. The study also included optional entry into an open-label
extension study.
Kraiprab 2005 was a double-blind study, similar to the other
studies described. In contrast to the other studies, this study was
performed at a single centre in Thailand and was an alternative-
dose-controlled study rather than a placebo-controlled study.
Participants were again recruited from an adult population, aged
18 to 65, who had drug-resistant focal epilepsy. Focal seizures could
be simple, complex, or focal seizures evolving into secondarily
generalised seizures. The study likewise had an 8-week prospective
baseline period, following which participants were randomised
to one of two treatment groups: either 1200 mg/d or 2400 mg/
d oxcarbazepine. Participants then entered a 2-week up-titration
period which then led into a 14-week maintenance period. ASer
completion, participants were oIered entry into an open-label
extension study.
NCT00975715 was a multi-centre, placebo-controlled, double-
blind study conducted at multiple sites, all of which were located
in Japan. Similar to Glauser 2000, this trial studied the eIicacy of
oxcarbazepine in children. Specifically, participants were aged 4 to
14 years with a diagnosis of focal onset seizures which could include
simple, complex, and secondarily generalised seizures. Participants
were randomised to receive either an oral suspension of either
oxcarbazepine (60 mg/ml) or placebo, although information on the
precise dosage was not provided. The study comprised an 8-week
prospective baseline period, followed by an 8-week treatment
period. The treatment period included a 2-week up-titration phase
and a 6-week maintenance phase. Participants then completed a 3-
to 5-week follow-up period.
Pina-Garza 2005 was also a multi-centre study involving 56
centres, distributed across seven countries: USA, Argentina, France,
Germany, Brazil, Mexico, and Lithuania. Rather than being placebo-
controlled, the study was instead alternative-dose-controlled and
participants were randomised to receive either a high dose of
oxcarbazepine (60 mg/kg/d) or a low dose of oxcarbazepine
(10 mg/kg/d). Interestingly, the study was not double-blind, but
was instead rater-blind, meaning that the outcome assessor was
blinded to treatment. Participants and their caregivers were not
blinded. This study was, however, conducted in a very young
population of participants, aged one month to four years old.
All participants had a diagnosis of focal seizures which included
subtypes: simple, complex, and focal evolving to secondarily
generalised seizures. Participants were initially screened over a 72-
hour period, prior to commencing a 24- to 72-hour baseline period.
The subsequent treatment periods varied in length, dependent
on the treatment group. Participants randomised to high-dose
oxcarbazepine (60 mg/kg/d) completed a 26-day titration period
followed by a 9-day maintenance period, whereas participants
randomised to low-dose oxcarbazepine (10 mg/kg/d) were not
required to undergo the 26-day titration period and, instead, only
completed the 9-day maintenance period. Following the treatment
period, there was then a 6-month open-label extension phase,
included in the study design.
Excluded studies
We excluded 15 records at the full-text screening stage. The 15
excluded records related to 13 individual studies. The reasons
for exclusion varied (see summarised in the Characteristics of
excluded studies tables). Notably, three records are still awaiting
classification.
We excluded three records from the review as they were
open-label extension studies with single-group assignment, and
thus lacked a control group (EUCTR2008-003334-19-BG; Glauser
2001; NCT00918424). We excluded a further two records as
they studied oxcarbazepine as a monotherapy (NCT00050947;
NCT01891890); whilst another record used oxcarbazepine to
replace carbamazepine in participants' drug regime and was
therefore deemed irrelevant (Houtkooper 1987). The latter study
also included a number of participants with generalised-onset
seizures which did not comply with the review inclusion criteria.
We found another record, Gillham 1993, to be linked to another
record, a study by McKee 1994. We excluded both records from the
review as they were deemed to be irrelevant. The study primarily
focused on investigating the pharmacokinetics of oxcarbazepine
and initially used oxcarbazepine as a monotherapy rather than as
an adjunctive therapy. We excluded an additional record, a trial
by Rey 2004, and a linked record, a poster abstract by Dulac 2001,
aSer it was revealed that the full-text record — Rey 2004 — did not
provide data for any of the outcomes defined in the review and also
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focused on the pharmacokinetics of oxcarbazepine. This study also
included participants with generalised epilepsy, which again made
it ineligible for inclusion as the authors did not report the outcomes
stratified by primary seizure type. We excluded one record because,
upon inspection of the full-text, we discovered that the record was
a meta-analysis of safety data taken from 21 studies, and was not a
randomised controlled trial (Kutluay 2003).
We excluded the remaining four studies because there were
no results available for the studies (EUCTR2004-002260-25-
AT; EUCTR2006-003834-14-DE; NCT00391534; SteinhoI 2012).
Notably, three records corresponded to studies which had been
terminated early due to low recruitment and, therefore, no
data were available (EUCTR2006-003834-14-DE; NCT00391534;
SteinhoI 2012). Similarly results were not reported for the
other record; consequently we also had to exclude this record
from the review (EUCTR2004-002260-25-AT). Additionally, aSer
we studied the EU clinical trial registration for the latter
record (EUCTR2004-002260-25-AT), it appeared that a certain
proportion of participants on the study received oxcarbazepine as a
monotherapy, not as an add-on ― therefore we suspected that the
study was ineligible for inclusion, regardless.
We further recognised that for another three of the records
highlighted in the searches, we required additional information
before being able to decide whether they were eligible for inclusion
in the review (CTRI/2010/091/000100; CTRI/2010/091/001194;
CTRI/2010/091/006085). These records have, therefore, been
acknowledged under studies awaiting classification (See
Characteristics of studies awaiting classification tables). At the
time of publication of this review, we had requested additional
information for the studies awaiting classification but had not yet
received it.
Risk of bias in included studies
We judged that three of the included studies were at an unclear
risk of bias overall (Glauser 2000; Kraiprab 2005; NCT00975715), and
rated that the remaining three studies were at a high risk of bias
(Barcs 2000; Pina-Garza 2005; French 2014). The rating for the risk
of bias, according to each bias domain, for each individual study
included, is described in detail below and can be found summarised
in Figure 2 and Figure 3 as well as in the 'Risk of bias' tables within
the Characteristics of included studies tables.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
We judged that three of the included studies had a low risk
of bias with regards to random sequence generation (Glauser
2000; Pina-Garza 2005; French 2014). One study specified that
a pseudo-random number generator was used (French 2014);
whilst another study stated use of a computer-generated schedule
for randomisation (Glauser 2000). The third study claimed
that randomisation was automated by an interactive voice
response system which automated the successful randomisation of
participants (Pina-Garza 2005).
Similarly, we assessed these three studies to be at low risk of
bias, resulting from allocation concealment (Glauser 2000; Pina-
Garza 2005; French 2014). Two studies used an interactive voice
response system which guarantees allocation concealment (Pina-
Garza 2005; French 2014). The other study employed a phone
call system were the investigator would call the central oIice for
allocation of a participant, again ensuring allocation concealment
(Glauser 2000).
We determined the other three studies to be at unclear risk of
bias across the two selection bias domains — random sequence
generation and allocation concealment — as no information
regarding either domain was provided by the study publications
(Barcs 2000; Kraiprab 2005; NCT00975715).
Blinding
We assessed that four of the included studies were at low risk
of performance and detection bias (Glauser 2000; Kraiprab 2005;
Pina-Garza 2005; French 2014). Three of the studies used matching
placebo, achieved by using capsules and tablets identical in
appearance to the active oxcarbazepine tablets (Glauser 2000;
Kraiprab 2005; French 2014). For these three studies, participants
were required to keep a seizure diary and therefore acted as the
outcome assessors (Glauser 2000; Kraiprab 2005; French 2014).
Given the successful blinding of both participants and personnel,
specifically those responsible for data entry and analysis ensured
by the matching placebo, we judged that outcome assessment
would be eIectively blinded. For this reason, we judged that these
three studies were at low risk of both performance and detection
bias (Glauser 2000; Kraiprab 2005; French 2014).
The fourth study did not use any blinding method but the
participants involved in the study were all below the age of
four so we agreed that blinding was unlikely to influence
the responsiveness of this population of participants (Pina-
Garza 2005). Accordingly, we awarded the study a low risk
of bias judgement for performance bias. With regards to
outcome assessment, an independent paediatric neurologist, not
otherwise involved in the study, assessed and recorded seizures.
Consequently, we also judged this study to be at low risk of
detection bias (Pina-Garza 2005).
No information regarding the blinding of either participants or
of outcome assessors was provided by a further two of the
study publications (Barcs 2000; NCT00975715). Notably, Barcs 2000
included adult participants and NCT00975715 included children
up to the age of 14 who could have been aIected by a lack of or
inadequate blinding. We thus assessed that these two studies were
at unclear risk of bias for the two domains of performance bias and
detection bias.
Incomplete outcome data
Although five of the included studies utilised a modified intention-
to-treat population for their eIicacy analysis and all fully reported
attrition (Barcs 2000; Glauser 2000; Pina-Garza 2005; French 2014;
NCT00975715), we only rated one of these studies to be at low risk
of attrition bias (Pina-Garza 2005). The study by Pina-Garza 2005
featured an overall attrition rate of 10.2% and the attrition was
evenly distributed between the two treatment groups — high-dose
and low-dose oxcarbazepine. In contrast two of the studies, Barcs
2000 and French 2014, reported very high attrition rates overall
(42.5% and 32.2%, respectively). Most notably, the rate of attrition
was not evenly distributed between the treatment groups. In both
studies, the attrition rate was considerably higher in the highest
oxcarbazepine dose group. For example in the study by Barcs 2000,
the attrition rate was 73.6% for the treatment group receiving 2400
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mg/d oxcarbazepine compared to 22.5% in the group given the
lowest dose, 600 mg/d oxcarbazepine. Additionally, French 2014
employed a highly modified intention-to-treat population for their
eIicacy analyses which excluded nearly 8% of the study population
from their subsequent analyses. As a result we judged that both
Barcs 2000 and French 2014 were at high risk of attrition bias.
Furthermore, in both Barcs 2000 and French 2014 approximately
a quarter of the participants who were randomised to the highest
dose treatment group (2400 mg/d oxcarbazepine) actually received
a lower dose of 1800 mg/d oxcarbazepine aSer being down-titrated.
As a consequence, the data reported regarding the tolerability and
eIicacy of 2400 mg/d oxcarbazepine is likely misrepresented, and
could potentially be regarded as misleading.
The remaining two studies, Glauser 2000 and NCT00975715, had
acceptable study attrition rates — 11.6% and 10.1% attrition,
respectively. Attrition was not evenly distributed between the
two treatment groups in either study, however. In the study by
Glauser 2000, the attrition rate for the oxcarbazepine treatment
group was double that of the placebo treatment group. For the
NCT00975715 study, the rate of attrition was nine times higher in
the oxcarbazepine group than in the placebo group (nine versus
one participant). For both studies the attrition rate remained below
20%, even in the oxcarbazepine treatment group (Glauser 2000;
NCT00975715). For this reason we judged the two studies to be at
unclear risk of bias, rather than at high risk of bias (Glauser 2000;
NCT00975715).
Despite not conducting an intention-to-treat eIicacy analysis, we
deemed the study by Kraiprab 2005 to be at low risk of attrition
bias. Kraiprab 2005 conducted a 'per protocol' analysis, rather
than an intention-to-treat analysis. This, however, only excluded
four participants from the study analyses. The overall attrition
rate for this study was relatively low (10.3%) and was evenly
distributed between treatment groups. Furthermore, we were able
to reinstate the excluded participants in our intention-to-treat
analysis conducted in this review and, therefore, the attrition did
not influence our findings or conclusions. As a result, we assessed
the risk of attrition bias as low for Kraiprab 2005.
Selective reporting
We judged all six included studies to be at low risk of reporting
bias (Barcs 2000; Glauser 2000; Kraiprab 2005; Pina-Garza 2005;
French 2014; NCT00975715). Although we were unable to retrieve
trial protocols for any of the studies, the outcomes defined in
the Methods section for each of the five published studies were
all clearly and fully reported in the respective Results sections
(Figure 4) (Barcs 2000; Glauser 2000; Kraiprab 2005; Pina-Garza
2005; French 2014). Similarly for the NCT00975715 study, the results
of the outcomes defined under the 'study details' of the relevant
ClinicalTrials.gov web page were then fully reported under the
'Results' tab. We therefore had no reason to suspect reporting bias
in either instance.
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Figure 4.   ORBIT Matrix for primary, secondary and harm (safety) outcomes to investigate reporting bias
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Figure 4.   (Continued)
 
Other potential sources of bias
We determined that three of the included studies were free of any
other sources of bias (Barcs 2000; Kraiprab 2005; French 2014). We
therefore awarded these three studies a low risk of bias rating for
this domain.
By contrast, we rated the NCT00975715 study as being at an unclear
risk of bias regarding other sources of bias. We do not have a full,
detailed publication for this study, hence we are unable to either
identify or dismiss any other potential sources of bias. We also
assessed Glauser 2000 to be at unclear risk of other bias because
the range of doses used was notably diIerent to the target dose
specified in the Methods section. Specifically, the lowest dose used
was 6.4 mg/kg/d which is dramatically lower than the 30 mg/kg/d
suggested dose. Additionally, we assessed the study by Pina-Garza
2005 to be at high risk of other potential sources of bias due to
the significantly longer treatment period noted for the high-dose
oxcarbazepine group, compared to the low-dose oxcarbazepine
group.
E8ects of interventions
See: Summary of findings for the main comparison
Oxcarbazepine compared to control for drug-resistant focal
epilepsy
Importantly, for the purposes of our analyses in this review we
reinstated any participants that had previously been excluded from
the analyses conducted within the original trial publications to
fully adhere to the intention-to-treat population principle. Within
the trial publications, modified intention-to-treat populations had
been implemented which incorrectly excluded participants who
would normally be eligible for inclusion in intention-to-treat
analyses. Unless specified, a fixed-eIect model was used for the
analyses performed. In instances where we identified significant
heterogeneity, we used a random-eIects model; this is declared in
the text below.
A summary of the most important outcomes for the main
comparison, oxcarbazepine versus control, are presented in
the Summary of findings for the main comparison. For the
purposes of this comparison, control treatment could be
placebo, an alternative antiepileptic drug, or a diIerent dose
of oxcarbazepine. Specifically, for the studies included in this
review the control treatment was either placebo or a diIerent
dose of oxcarbazepine. We did not identify any eligible studies
that compared oxcarbazepine to an alternative antiepileptic drug.
For this comparison, we pooled all data regardless of dose of
oxcarbazepine used, age of participants, or treatment duration.
Subsequent to completing the meta-analysis for the main
comparison, we then considered how these variables might have
aIected the eIect size estimates and whether these variables
were possible sources of heterogeneity by conducting various
subgroup analyses. Based on the study data collected, we stratified
data for the subgroup analyses according to: control group used
(placebo and alternative oxcarbazepine dose subgroups); age
group included (adults and children); duration of treatment period
(8 weeks or less, 16 weeks, and 26 weeks); and oxcarbazepine dose
(600 mg, 1200 mg, and 2400 mg oxcarbazepine).
Median percentage seizure reduction per 28 days
Median values cannot be incorporated into a meta-analysis. As
a result the outcome — median percentage seizure reduction —
must be described narratively. Five studies, consisting of 1494
participants, reported median percentage seizure reduction per 28
days for participants randomised to oxcarbazepine (Barcs 2000;
Glauser 2000; Kraiprab 2005; Pina-Garza 2005; French 2014). The
median percentage seizure reduction for participants randomised
to placebo add-on treatment was reported by three studies (Barcs
2000; Glauser 2000; French 2014). The values reported ranged from
7.6% to 28.7% seizure reduction, with two of the three studies
specifically reporting percentage reductions of less than 10% (Barcs
2000; Glauser 2000). The median percentage seizure reduction for
participants randomised to experimental oxcarbazepine treatment
ranged from 26% to 83.3%. Notably, in studies which tested
multiple doses of oxcarbazepine (Barcs 2000; Kraiprab 2005; Pina-
Garza 2005; French 2014), the higher doses were associated with
a greater median percentage reduction in seizure frequency. For
example in the Barcs 2000 study, the median percentage seizure
reductions were 26%, 40% and 50% for participants allocated to
600 mg/d, 1200 mg/d and 2400 mg/d oxcarbazepine, respectively.
Importantly, for each study that described this outcome the median
percentage seizure reduction reported was consistently higher in
experimental oxcarbazepine treatment group than in the control
group.
50% or greater reduction in seizure frequency
All six studies (Barcs 2000; Glauser 2000; Kraiprab 2005; Pina-Garza
2005; French 2014; NCT00975715), involving 1593 participants,
contributed to Analysis 1.1. We detected significant heterogeneity
within the data set (P = 0.006, I2 = 70%) and consequently used
a random-eIects model to combine the data. The responder rate
was significantly higher in the experimental oxcarbazepine group,
compared to the control group (RR 1.80, 95% CI 1.27 to 2.56, P <
0.001). We completed subgroup analysis stratified by the nature
of the control group (Analysis 2.1); the age of the clinical sample
(Analysis 3.1); the duration of the treatment period (Analysis 4.1);
and the dose of experimental oxcarbazepine (Analysis 5.1).
Subgroup analyses stratified by the type of control group (P =
0.03, I2 = 79.8%; Analysis 2.1) and by the duration of the treatment
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period (P = 0.01, I2 = 77.9%; Analysis 4.1) demonstrated a significant
subgroup eIect for the responder rate. This implies that both the
type of control group used and the duration of the treatment period
might explain some of the statistical heterogeneity observed.
Interestingly, a substantial amount of statistical heterogeneity
remained despite stratifying the data according to the clinical and
design-dependent subgroups. With respect to the control group
used, a much larger, statistically significant treatment eIect was
observed in studies utilising a placebo-controlled design (RR 2.09,
95% CI 1.69 to 2.59, P < 0.001) compared to the insignificant eIect
observed in studies using an alternative-dose-controlled study
design (RR 1.36, 95% CI 0.99 to 1.86, P = 0.06; Analysis 2.1). Notably,
only two small-sample studies contributed data to the alternative-
dose-controlled subgroup. The results between the two studies
were nevertheless very consistent. Specifically, the magnitude of
the eIect size observed was much greater with a treatment period
of 26 weeks (RR 3.09, 95% CI 2.06 to 4.64, P < 0.001) than with a
treatment period of 16 weeks or less (RR 1.51, 95% CI 1.20 to 1.92,
P < 0.001; Analysis 4.1). It should be noted, however, that the data
for the 26-week duration subgroup was taken from a single study
(Barcs 2000). Subgroup analysis stratified by the age of participants
did not reveal a significant subgroup eIect (P = 0.49) (Analysis
3.1). Although it was not possible to conduct a test for subgroup
diIerences for Analysis 5.1 (subgroup analysis stratified by the dose
of experimental oxcarbazepine used), the magnitude of change
in risk ratios between doses was not suIiciently great. Notably,
the confidence intervals for each risk ratio calculated considerably
overlapped and there was no clear clustering of data points for
each subgroup. This suggests that there is not a dose-dependent
subgroup eIect for the outcome of 50% or greater reduction in
seizure frequency.
Adverse e8ects
We investigated the incidence rate of 19 diIerent adverse eIects.
There was no statistically significant diIerence in the incidence of
11 of the suggested adverse eIects detected between participants
randomised to the experimental oxcarbazepine group and those
randomised to the control group. The 11 adverse eIects were:
ataxia (Analysis 1.2), nausea (Analysis 1.5), headache (Analysis 1.7),
hyponatraemia (Analysis 1.8), rash (Analysis 1.11), tremor (Analysis
1.12), pyrexia (Analysis 1.13), abdominal pain (Analysis 1.15), viral
infection (Analysis 1.17), abnormal vision (Analysis 1.19), and upper
respiratory tract infection (Analysis 1.20).
The remaining eight adverse eIects investigated are described
below.
1. Dizziness was reported in four studies, consisting of 1336
participants (Analysis 1.3). The incidence of dizziness was
significantly greater in the experimental oxcarbazepine group
compared to the control group (RR 2.58, 99% CI 1.81 to 3.68, P
< 0.001).
2. Fatigue was reported in four studies, consisting of 1336
participants (Analysis 1.4). The incidence of fatigue was
significantly higher in the experimental oxcarbazepine group
than in the control group (RR 1.88, 99% CI 1.07 to 3.32, P = 0.004).
3. Somnolence was reported by all six studies, involving a total of
1593 participants (Analysis 1.6). Significant heterogeneity (P =
0.03, I2 = 59%) was detected within the data set. Consequently,
a random-eIects model was used for the analysis. Participants
in the experimental oxcarbazepine group were twice as likely to
experience somnolence as participants in the control group (RR
2.03, 99% CI 1.17 to 3.54, P = 0.001).
4. Vertigo was reported in two studies, involving 793 participants
(Analysis 1.9). Participants in the experimental oxcarbazepine
group were over four times more likely to experience vertigo
than those in the control group (RR 4.62, 99% CI 1.32 to 16.13, P
= 0.002).
5. Diplopia was reported by five studies, including 1465
participants (Analysis 1.10). Participants in the experimental
oxcarbazepine group were over five times more at risk of
experiencing diplopia than those in the control group (RR 5.50,
99% CI 2.83 to 10.68, P < 0.001).
6. Abnormal gait was reported by only two studies with 961
participants included in the analysis (Analysis 1.14). Participants
in the experimental oxcarbazepine group were over five times
more likely to experience abnormal gait changes than those in
the control group (RR 5.53, 99% CI 1.74 to 17.61, P < 0.001).
7. Nystagmus was reported by two studies, involving 961
participants (Analysis 1.16). The incidence of nystagmus was
over four times greater in the experimental oxcarbazepine group
than in the control group (RR 4.56, 99% CI 1.90 to 10.94, P <
0.001).
8. Vomiting was reported in all six studies, including a total
of 1593 participants (Analysis 1.18). Significant heterogeneity
(P = 0.06, I2 = 54%) was detected within the data set. A
random-eIects model was, therefore, used for the analysis.
Participants receiving experimental oxcarbazepine treatment
were significantly more likely to experience vomiting than
participants receiving control treatment (RR 2.55, 99% CI 1.20 to
5.42, P = 0.001).
Seizure freedom
Five of the included studies involving 1494 participants contributed
to the following outcome analysis (Barcs 2000; Glauser 2000;
Kraiprab 2005; Pina-Garza 2005; French 2014). Significant
heterogeneity was detected within the data set (P = 0.08, I2
= 51%); therefore, we utilised a random-eIects model for the
outcome analysis. Participants randomised to the experimental
oxcarbazepine group were nearly three times more likely to attain
seizure freedom than were participants randomised to a control
group (RR 2.86, 95% CI 1.19 to 6.87, P = 0.02).
We conducted multiple subgroup analyses to explore the
possible reasons for the observed heterogeneity. Subgroup
analysis stratified by control group, specifically whether the study
was placebo-controlled or alternative-dose-controlled, displayed
significant heterogeneity between the two subgroups (P = 0.02,
I2 = 81.1%, Analysis 2.2). Notably, in placebo-controlled studies
participants receiving oxcarbazepine were six times more likely to
achieve seizure freedom than participants receiving placebo (RR
6.14, 95% CI 2.62 to 14.41, P < 0.01). In contrast, a significant
diIerence in the likelihood of achieving seizure freedom was not
detected between participants receiving high-dose versus low-
dose oxcarbazepine in alternative-dose-controlled studies (RR 1.45,
95% CI 0.58 to 3.62, P = 0.08).
Subgroup analysis stratified by age of study population (P = 0.10;
Analysis 3.2) and duration of treatment period (P = 0.08; Analysis
4.2) did not display a significant subgroup eIect for the outcome
'seizure freedom'. Despite this, the risk ratio calculated for adults
(RR 5.19, 95% CI 2.29 to 11.75) was notably larger compared
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to that calculated for children (RR 2.16, 95% CI 1.13 to 4.14).
Likewise, within the treatment period subgroup analysis, 26 weeks'
treatment period demonstrated a much larger treatment eIect
(RR 20.26, 95% CI 2.83 to 145.02) for oxcarbazepine compared to
placebo over the shorter treatment duration lengths (8 weeks or
less: RR 1.90, 95% CI 0.96 to 3.76; 16 weeks: RR 2.41, 95% CI 1.05 to
5.52). Specifically, Barcs 2000 was the only study to supply data to
the 26-week treatment period subgroup and was also one of only
three studies to contribute data to the adult subgroup. Barcs 2000
predicted a very large risk ratio (RR 20.26, 95% CI 2.83 to 145.02)
which most likely skewed the adult subgroup. Whilst it is clear
that this result is an outlier compared to the other results within
the adult subgroup, it is still worth considering that adults could
potentially respond better to oxcarbazepine than children. Similar
observation apply to treatment duration for seizure freedom.
Subgroup analysis stratified by dose of experimental
oxcarbazepine did not demonstrate a clear eIect of dose on the
estimated eIect (Analysis 5.2). Again, Barcs 2000 predicted much
larger treatment eIects, dependent on dose, compared to the other
included studies in the subgroups. Due to the heterogeneity and
inconsistency of the data within the individual dose subgroups, we
did not consider that dose explained the heterogeneity observed
across the entire dataset.
Treatment withdrawal
All six included studies (Barcs 2000; Glauser 2000; Kraiprab 2005;
Pina-Garza 2005; NCT00975715; French 2014), comprising 1593
participants, contributed to this outcome analysis. We did not
detect significant heterogeneity (P = 0.55, I2 = 0%) within this
data set for the main comparison — oxcarbazepine versus control
— and therefore we continued to utilise the fixed-eIect model
for this outcome analysis. Participants receiving experimental
oxcarbazepine treatment were significantly more likely to withdraw
from treatment. Specifically, participants receiving experimental
oxcarbazepine were 75% more likely than participants receiving the
control treatment to withdraw from treatment (RR 1.75, 95% CI 1.44
to 2.13, P < 0.001; Analysis 1.22).
Although we did not detect any statistical heterogeneity within the
data set, we continued to conduct subgroup analysis to determine
whether any undetected clinical or methodological heterogeneity
might exist. Although we were unable to conduct the test for
subgroup diIerences for the subgroup analysis stratified by the
experimental dose of oxcarbazepine used (Analysis 5.3), due to
the overlap in placebo participants between subgroups, we were
able to identify clear diIerences between the subgroups, based
on the risk ratios calculated. The rate of treatment withdrawal
was significantly higher for participants randomised to both 1200
mg/d (RR 1.95, 95% CI 1.50 to 2.52, P < 0.001) and 2400 mg/d
oxcarbazepine (RR 2.38, 95% CI 1.92 to 2.94, P < 0.001). Participants
randomised to both treatment groups were approximately twice
as likely to withdraw from treatment as those receiving placebo.
On the other hand, the treatment withdrawal rates for participants
receiving 600 mg/d oxcarbazepine and those receiving control were
not significantly diIerent (RR 0.79, 95% CI 0.55 to 1.15, P = 0.22).
Subgroup analysis stratified by the type of control group (P = 0.52;
Analysis 2.3), the age of the clinical sample (P = 0.29; Analysis 3.3),
and the duration of treatment period (P = 0.51; Analysis 4.3) did
not display a significant subgroup eIect for the outcome 'treatment
withdrawal'.
Quality of life and cognitive e8ects
Only French 2014, involving 366 participants, measured and
reported quality of life. French 2014 used the Quality of Life
in Epilepsy (QOLIE-31) questionnaire which includes a subscale
score for cognitive functioning. This enabled the study to assess
both the quality of life of participants and, potentially, any
perceived cognitive eIects. French 2014 reported that the mean
total QOLIE-31 and subscale scores did not decrease from baseline
for any of the treatment groups: 1200 mg/d oxcarbazepine,
2400 mg/d oxcarbazepine, or placebo. This highlights that, most
importantly, there was no decrease in quality of life resulting
from active treatment. The 1200 mg/d treatment group did,
however, demonstrate a significantly smaller increase in the
QOLIE-31 subscale of Cognitive Functioning. Additionally, there
was a significantly smaller increase in the Medication EIects for
both the 1200 mg/d oxcarbazepine and 2400 mg/d oxcarbazepine
treatments groups, compared to placebo.
D I S C U S S I O N
Summary of main results
This review included data from six randomised controlled trials
(Barcs 2000; Glauser 2000; Kraiprab 2005; Pina-Garza 2005; French
2014; NCT00975715), involving a total of 1593 participants. We
judged that three of the included studies were at unclear risk of
bias (Glauser 2000; Kraiprab 2005; NCT00975715); and the other
three were at high risk of bias (Barcs 2000; Pina-Garza 2005; French
2014). Most of the concerns about bias arose from the lack of details
provided regarding the randomisation and allocation concealment
of participants. There were also concerns about the high attrition
rate noted in several of the studies. The attrition rate was especially
problematic in the treatment groups receiving the higher doses of
oxcarbazepine.
Treatment with oxcarbazepine was associated with an increased
responder rate (the number of participants achieving a 50% or
greater reduction in seizure frequency), as well as an increased
incidence of seizure freedom compared to control treatment. Both
of these outcomes were, however, derived from low-certainty
evidence, according to GRADE assessment, meaning that we cannot
be certain about the accuracy of these results. Interestingly, when
the data were subjected to subgroup analyses, both outcomes
were associated with a statistically significant subgroup eIect
when stratified by the type of control group utilised (placebo or
alternative dose). Specifically, experimental oxcarbazepine was
revealed to have a much greater treatment eIect with regards to
seizure freedom and responder rate when compared to placebo
control rather than when compared to an alternative, lower dose of
oxcarbazepine.
Additionally, the responder rate also demonstrated a significant
subgroup eIect when stratified by the duration of the treatment
period. Oxcarbazepine given over the longest treatment period
(26 weeks) demonstrated a much larger treatment eIect size
for responder rate than oxcarbazepine given over the shorter
treatment periods. Importantly, however, Barcs 2000 was the only
study which had a treatment period of 26 weeks and was, therefore,
the only study to contribute data to this subgroup for the analysis.
Although the study by Barcs 2000 contained a large sample size (694
participants), the fact that the subgroup analysis is derived from
a single study should be considered when interpreting the results.
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Of further significance, Barcs 2000 was also a placebo-controlled
study. As previously described, subgroup analysis according to
control group revealed that oxcarbazepine was shown to have
a greater therapeutic eIect when compared to placebo, and
therefore it is possible that these two trial characteristics — the
nature of the control group and the treatment duration — could be
confounding the results between the two subgroup analyses (Barcs
2000; Pina-Garza 2005; French 2014).
With regards to tolerability, treatment with experimental
oxcarbazepine increased the treatment withdrawal rate compared
to that observed with control treatment. The evidence was of
moderate certainty for this outcome, suggesting that this finding
is likely to be accurate. Subgroup analyses for the outcome
'treatment withdrawal' revealed clear diIerences in the treatment
eIect predicted for subgroups when the data were stratified
according to dose of experimental oxcarbazepine. The largest
oxcarbazepine dose, 2400 mg/d, was associated with a larger
treatment withdrawal rate compared to control than was 1200
mg/d or 600 mg/d oxcarbazepine. Treatment with experimental
oxcarbazepine was furthermore associated with an increased
incidence rate for several of the adverse eIects included in the
review, namely: dizziness, fatigue, somnolence, vertigo, diplopia,
abnormal gait, nystagmus, and vomiting.
Notably, we analysed data for a total of 19 adverse eIects and
consequently the likelihood of type I and type II statistical errors
occurring was significantly increased. Although care must therefore
be taken when interpreting the results, the findings regarding
the adverse eIects are consistent with the increased treatment
withdrawal rate observed. In short-term studies, treatment
withdrawal most commonly relates to adverse eIects experienced
rather than reflecting a lack of eIicacy. This consequently implies
that the increased occurrence of adverse eIects is a true eIect of
oxcarbazepine treatment.
To summarise, our review has indicated that oxcarbazepine may
display a therapeutic eIect, as demonstrated by the significantly
increased responder and seizure freedom rate compared to control.
Uncertainty about this finding arises, however, from the low-
certainty evidence used to derive this finding. Our review has
also highlighted issues with the tolerability of oxcarbazepine,
specifically at higher dosages, which is reflected in the increased
treatment withdrawal rate.
Overall completeness and applicability of evidence
As part of this review, we had hoped to explore the eIect of
oxcarbazepine on quality of life and cognition. Unfortunately,
however, only one of the included studies investigated and
reported quality of life (French 2014). Notably, the questionnaire
used to assess quality of life did include an element whereby
participants were asked to evaluate their own cognition; this clearly
requires self-report, however, and is not a thorough examination
of cognitive ability. As a result, we are not adequately informed
to comment on the eIects of oxcarbazepine on either outcome.
A thorough neuropsychological assessment with more rigorous
cognitive testing, focusing on assessing memory, attention and
psychomotor speed, would be necessary to determine whether
oxcarbazepine does impact cognitive function.
Separate from this, we had also specified that we would conduct
multiple subgroup analyses to investigate any potential clinical or
statistical heterogeneity. Given that only six studies were eligible
for inclusion in the review originally, the splitting of data into
subgroups may have led to some subgroups being underpowered.
Some subgroups contained data from only one study, whilst other
subgroups contained very low numbers of participants, despite
including data from multiple studies. For this reason, caution is
required when considering, or applying, any of the findings derived
from the subgroup analyses performed in this review.
Certainty of the evidence
For this review, we assessed that three of the studies were
at high risk of bias (Barcs 2000; Pina-Garza 2005; French
2014); and the other three studies were at unclear risk of
bias (Glauser 2000; Kraiprab 2005; NCT00975715). Three studies
failed to provide specific information regarding the method for
randomisation and allocation concealment (Glauser 2000; Kraiprab
2005; NCT00975715). A further two studies did not describe how
eIective blinding was achieved and maintained (Barcs 2000;
NCT00975715). There were additional concerns regarding attrition
bias. We rated two of the studies as being at high risk of attrition
bias, as they both had attrition rates that well exceeded 20% of
the randomised population (Barcs 2000; French 2014). By contrast,
we deemed another two studies to be at unclear of risk of attrition
bias because the attrition rate was below 20% of the randomised
population, but was not balanced across the treatment groups
(Glauser 2000; NCT00975715).
The serious risk of bias, detected across the studies, led to us
downgrading the certainty of evidence to moderate certainty for
each of the outcomes included in the GRADE assessment. We
rated the evidence as moderate certainty both for the incidence
of treatment withdrawal and for the incidence of the adverse
eIects 'ataxia' and 'hyponatraemia', meaning that we are fairly
certain that the conclusions made regarding these outcomes
are accurate. Further concerns about the significant statistical
heterogeneity detected across the data set for the eIicacy
outcomes 'responder rate' and 'seizure freedom' resulted in the
certainty of evidence being downgraded again to low certainty for
these two outcomes. Notably, seizure freedom was downgraded
again due to imprecision, based on the sub-optimal number of
events constituting the analysis, but was upgraded back to low
certainty because of the large eIect size recognised. Similarly,
the certainty of evidence for the adverse eIects 'nausea' and
'somnolence' were further downgraded to very low and low,
respectively, due to serious statistically significant heterogeneity
and imprecision.
For the outcomes for which the evidence was rated as either low
or very low certainty, this means that we are less certain that the
eIect size calculated, and consequently the conclusions reached,
are accurate about the true eIect of oxcarbazepine.
Potential biases in the review process
During the screening process, we recognised several
studies that appeared to be eligible for inclusion
in the review (CTRI/2010/091/000100; CTRI/2010/091/001194;
CTRI/2010/091/006085). We were unable to obtain the data
or methodological details for the trials, however, despite
contacting the relevant authors and pharmaceutical companies.
Consequently, we could not assess these studies for inclusion
and they are therefore listed in the Studies awaiting classification
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section of the text. Additional data would have strengthened the
review and improved the robustness of the subgroup analysis.
Importantly, additional data could also potentially change the
conclusions of the review and, therefore, the missing studies must
be regarded as a weakness of this review. Future updates of this
review should seek whether the results of these trials have yet been
published.
We similarly contacted the study authors and sponsoring
pharmaceutical companies of the studies included in the review
to request the associated trial protocols. Unfortunately, we were
only supplied with the trial protocol for Pina-Garza 2005. This was
especially problematic for the NCT00975715 trial, for which the
results have not been formally published. This meant that we had
limited information regarding the methodological design of the
trial. We could have gained this information from the trial protocol,
had it been provided.
Another potential issue with this review was alluded to earlier.
In this review, we assessed and analysed numerous outcomes.
Conducting multiple statistical comparisons increases the risk
of type I and type II statistical errors occurring. Additionally,
multiple subgroup analyses were also performed which were all
largely underpowered. It is therefore possible that some of the
conclusions described could be inaccurate, despite displaying
statistical significance, as a result of these type I and type II errors.
In future revisions of this review, it would be advisable to limit the
number of outcomes measured, and impose restrictions on when
a subgroup analysis can be conducted, to improve the reliability of
these statistical assessments.
Agreements and disagreements with other studies or
reviews
Multiple other reviews have similarly reported that oxcarbazepine
is eIicacious at reducing seizure frequency in drug-resistant
epilepsy (Kalis 2001; Bang 2003; Saconato 2009). Specifically, the
review by Bang 2003 stated that 20% to 54% of trial participants
experience a 50% of greater reduction in seizure frequency whilst
receiving oxcarbazepine. Comparably in our review, across the six
studies we analysed we found that 23% to 59% of participants
experience 50% or greater seizure reduction when randomised to
oxcarbazepine. Notably, however, the review by Bang 2003 was
a narrative summary of data which collected from four studies,
including three non-comparative studies, and was not a meta-
analysis.
In contrast, the review by Saconato 2009 did include a meta-
analysis of data extracted from four randomised controlled trials
to investigate oxcarbazepine for drug-resistant epilepsy. Saconato
2009 similarly emphasised that significantly more participants
achieved a 50% or greater reduction in seizure frequency when
receiving oxcarbazepine compared to when receiving placebo.
During the meta-analysis, however, Saconato 2009 detected an
increase in the risk ratio for 50% or greater seizure reduction
responder rate with increased dosages of oxcarbazepine (600 mg/
d: RR 2.11, 95% CI 1.32 to 3.35; 1200 mg/d: RR 3.24, 95% CI 2.11
to 4.98; 2400 mg/d: RR 3.83; 95% CI 2.59 to 5.97). In our own
subgroup analysis according to dosage, we observed that the risk
ratio for 50% or greater seizure reduction remained around 2.00,
regardless of oxcarbazepine dose; thus we were unable to replicate
their finding in our current review.
Importantly, in their review the calculated risk ratios only included
data from one study which consisted of a purely adult study
population: namely, the RCT by Barcs 2000, which was also
included in our current review. In our review, we have included
data from up to three studies for each of the subgroups
during the subgroup analysis, stratified by dose of experimental
oxcarbazepine. Furthermore, with our review being more recently
published, it contains more up-to-date evidence for the eIect
of oxcarbazepine. Specifically, our review contains the latest
publication by French 2014, which would not have been available
at the time of publication for Saconato 2009. As a result, our
calculated risk ratios should provide a more robust and accurate
estimation of the oxcarbazepine treatment eIect as it incorporates
more data from multiple sources.
Similarly, the risk ratios for seizure freedom (1200 mg/d: RR
17.59, 95% CI 2.37 to 130.35; 2400 mg/d: RR 25.41, 95% CI
6.26 to 103.10), calculated by Saconato 2009, were much greater
than those reported here. Again, they mainly relied upon data
extracted from Barcs 2000 with only the risk ratio calculated for
the highest oxcarbazepine dose (2400 mg/d) including data from
an additional smaller study. Notably, one of the RCTs included in
the meta-analysis by Saconato 2009 utilised oxcarbazepine as a
monotherapy rather than as an adjunctive therapy, which could
further explain any observed diIerences in our reported findings.
The review by Saconato 2009 did, however, comment that
the trials which were included in the meta-analysis were of
medium to poor methodological quality. Saconato 2009 likewise
highlighted the lack of methodological details regarding random
sequence generation and allocation concealment which led to their
judgement. Similarly in this review, there was an issue with the
quality and certainty of studies, such that we judged all of the
included studies to be at either a high or unclear risk of bias, which
is a partial reflection of methodological quality.
In contrast to our review, many other reviews and long-term
extension studies report that oxcarbazepine is well tolerated
(Beydoun 2002; Walker 2002; Bang 2003). Many reviews specifically
emphasise the increased tolerability of oxcarbazepine compared
to carbamazepine, the molecule from which oxcarbazepine is
structurally derived (Krämer 2000; Arroyo 2001; Kalis 2001; Horga
de la Parte 2006). This mainly appears to be due to the reduced
potential for drug interactions, resulting from enzyme induction,
noted with oxcarbazepine (Kalis 2001). In this review, we have
instead highlighted issues with the tolerability of oxcarbazepine,
especially when participants are titrated to the higher doses.
Notably, treatment withdrawal was less problematic and less
prevalent in the lower oxcarbazepine dose subgroups.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review provides limited information about the eIicacy and
tolerability of oxcarbazepine as an add-on therapy for people with
drug-resistant focal epilepsy. Although the evidence presented
here did demonstrate that oxcarbazepine eIectively reduces
seizure frequency, the evidence for this outcome was of low
certainty. Consequently, we cannot be certain that this finding is
accurate. By contrast, with regards to tolerability the evidence for
treatment withdrawal was of moderate certainty, and thus should
be a fairly accurate estimate of the true eIect of oxcarbazepine.
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This review revealed an increased treatment withdrawal rate for
participants who receive oxcarbazepine compared to those who
receive control. Moreover, people receiving oxcarbazepine were
shown to be more at risk of experiencing several diIerent adverse
eIects.
We suspect that there are issues with the tolerability of
oxcarbazepine that are especially prevalent at the higher doses
of oxcarbazepine. We observed higher treatment withdrawal rates
with increased oxcarbazepine dose. Of further importance, as
we have highlighted in Incomplete outcome data (attrition bias)
subsection, tolerability could be underestimated for the highest
dose of oxcarbazepine (2400 mg/d), due to the down-titration of
approximately a quarter of randomised participants from 2400 mg/
d to 1800 mg/d. Consequently, we are unable to provide a reliable
interpretation of the tolerability of oxcarbazepine at the highest
dose but infer that there are serious issues with tolerability at 2400
mg/d oxcarbazepine.
Implications for research
Additional studies are necessary to correctly inform clinical
practice. Specifically, we require more clinical trials which
investigate multiple doses of oxcarbazepine to be conducted and
which vary in treatment duration and type of control group. The
data from these trials could then be incorporated into an updated
review in order to adequately power the subgroup analyses
presented here. Additional studies incorporating multiple doses
are especially important to resolve whether the concerns regarding
tolerability are notable with all doses of oxcarbazepine or are
solely a feature of the higher doses of oxcarbazepine. Longer-
term trials are also desirable as they are able to assess the long-
term tolerability of drugs, and can further establish whether drug
tolerance develops.
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Randomised, double-blind, PBO-controlled, 4-arm, parallel-group, multi-centre (73 centres, 11 coun-
tries)
Duration
1. Prospective baseline period (8 weeks)
2. Treatment period with titration (2-week up-titration, 24-week maintenance)
3. 2-week tapering period or entry into open-label extension
Participants Randomised population
OXC 600 mg/d: 169
OXC 1200 mg/d: 178
OXC 2400 mg/d: 174
PBO: 173
ITT population
OXC 600 mg/d: 168
OXC 1200 mg/d: 177
OXC 2400 mg/d: 174
PBO: 173
Safety population
OXC 600 mg/d: 168
OXC 1200 mg/d: 177
OXC 2400 mg/d: 174
PBO: 173
No. of participants excluded from analyses
OXC 600 mg/d group: 1
OXC 1200 mg/d group: 1
Excluded due to premature discontinuation before taking any trial medication
Age (mean and range)
≥ 15 to 65 years
OXC 600 mg/d = 34.6 (15 to 65)
OXC 1200 mg/d = 33.8 (16 to 64)
OXC 2400 mg/d = 35.2 (15 to 66)
PBO = 34.3 (15 to 65)
Gender, male, n (%)
OXC 600 mg/d = 86 (51.2)
OXC 1200 mg/d = 80 (45.2)
Barcs 2000  (Continued)
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OXC 2400 mg/d = 98 (56.3)
PBO = 77 (44.5)
Types of seizure
Uncontrolled focal-onset seizures (simple, complex, or focal seizures evolving to secondarily gener-
alised seizures)
Seizure frequency during baseline (median)
OXC 600 mg/d = 9.6
OXC 1200 mg/d = 9.8
OXC 2400 mg/d = 10.0
PBO = 8.6
Interventions OXC 600 mg/d (twice daily)
OXC 1200 mg/d (twice daily)
OXC 2400 mg/d (twice daily)
PBO (twice daily)
Outcomes Primary outcome
1. Percentage reduction in seizure frequency per 28 days during the treatment period relative to base-
line.
Secondary outcomes
1. Responder rate (≥ 50% reduction in seizure frequency in the treatment period relative to baseline).
Safety and tolerability outcomes
1. Physical and neurologic examination
2. Vital signs
3. Laboratory tests
4. Adverse events (AEs)
Notes Sponsored by Novartis Pharma AG and conducted on behalf of International Oxcarbazepine (OT/PE1)
Study Group
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of randomisation was not provided
Allocation concealment
(selection bias)





Unclear risk Comment: method of blinding participants and personnel was not provided
Barcs 2000  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Patients kept a diary throughout the maintenance period and record-
ed the date and time of each seizure."
Comment: method of blinding for participants, and therefore outcome asses-
sors, is not provided. No other information regarding the blinding of outcome




High risk Quote from table: “[OXC 2400 mg/d treatment group] Includes 47 patients
treated with OXC 1800 mg/d; 43 of the 47 patients were randomized directly to
OXC 1800 mg/d, and 4 of the 47 patients were reduced from OXC 2400 to OXC
1800 mg/d. Twelve of 46 patients in the OXC 2400 mg/d group, who completed
the trial, were treated with OXC 1800 mg/d”
Quote from text: "A protocol amendment was prepared to allow for a blind-
ed reduction to 1800 mg/d OXC in the 2400 mg/d OXC treatment group either
directly after randomization or on the occurrence of tolerability problems or
AEs... For the primary efficacy variable, no distinction was made between pa-
tients who received 2400 mg/d OXC and those who received 1800 mg/d OXC af-
ter implementation of the amendment, because these two doses still formed a
distinct randomized group; the subdivision was not subject to randomization."
Comment: modified intention-to-treat analysis performed and attrition report-
ed; however, study had an attrition rate of 42.5%. Highest attrition rate (73.5%)
was reported for the 2400 mg/d oxcarbazepine treatment group. Additionally,
categorising data from participants receiving 1800 mg/d under the 2400 mg/d
treatment group provides unreliable and misleading data regarding the toler-
ance and efficacy of OXC at the 2400 mg dose level.
Selective reporting (re-
porting bias)
Low risk Comment: protocol was not provided; however, all outcomes defined in Meth-
ods were reported in Results





Randomised, double-blind, PBO-controlled, parallel-group, multi-centre (88 centres, 8 countries: USA,
Mexico, Canada, Russia, Poland, Bulgaria, Croatia, Romania)
Duration
1. Prospective baseline period (8 weeks)
2. Treatment period with titration (4-week titration, 12-week maintenance period)
3. 3-week blinded conversion period to open-label treatment or tapering to baseline therapy
Participants Randomised population
OXC 1200 mg/d: 122
OXC 2400 mg/d: 123
PBO: 121
ITT population
OXC 1200 mg/d: 109
OXC 2400 mg/d: 111
French 2014 
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PBO: 117
Safety population
OXC 1200 mg/d: 122
OXC 2400 mg/d: 123
PBO: 121
No. of participants excluded from analyses
OXC 1200 mg/d group: 13
OXC 2400 mg/d group: 11
PBO: 4
Excluded due to the absence of analysable data.
Age (mean ± SD)
≥ 18 to 65 years
OXC 1200 mg/d = 39.1 (11.5)
OXC 2400 mg/d = 38.5 (11.6)
PBO = 39.1 (12.5)
Gender, male, n (%)
OXC 1200 mg/d = 71 (58.2)
OXC 2400 mg/d = 64 (52.0)
PBO = 67 (55.4)
Types of seizure
Focal-onset seizures with or without secondary generalisation
Seizure frequency during baseline (median)
OXC 1200 mg/d = 6.0
OXC 2400 mg/d = 6.0
PBO = 7.0
Interventions OXC 1200 mg/d (Once daily)
OXC 2400 mg/d (Once daily)
PBO (Once daily)
Outcomes Primary outcome
1. Median percentage change in seizure frequency per 28 days during the 16-week treatment period rel-
ative to baseline.
Secondary outcomes
1. Responder rate (≥ 50% reduction in seizure frequency in the treatment period relative to baseline)
2. Proportion of patients seizure free
French 2014  (Continued)
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3. Changes in PGIC and QOLIE-31 scores
Safety and tolerability outcomes
1. Treatment emergent adverse events (TEAEs)




Notes Sponsored by Supernus Pharmaceuticals Inc.
Trial registration number: NCT00772603
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was managed by a centralized interactive voice re-
sponse system, with the vendor using a pseudo-random number generator to
produce study drug kit numbers for the randomization schedule."
Allocation concealment
(selection bias)
Low risk Quote: "Randomization was managed by a centralized interactive voice re-
sponse system, with the vendor using a pseudo-random number generator to





Low risk Quote: "Study drug blinding was maintained with identical 600-mg SPN-804 or
placebo tablets and packaging in blister cards."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "During the double-blind treatment period, patients and all personnel
involved with the study’s conduct or interpretation remained blinded to study
drug codes."
Comment: participants were required to keep a seizure diary and therefore
acted as the efficacy outcome assessors. Participants and personnel, including




High risk Quote: "Efficacy was assessed in the intent-to-treat population with analyz-
able seizure data, that is, all randomized patients with seizure data for ≥21
consecutive days in the baseline phase who received at least one dose of study
drug, had at least one on-treatment visit, and ≥14 consecutive days of seizure
diary data after study drug receipt."
Quote: “After week 4, study drug could be down-titrated if needed by discard-
ing the last tablet on each blister pack row, thereby blindly reducing the dose
only in the SPN-804 2400-mg group (reduced to 1800 mg/day)... Patients as-
signed to SPN-804 2400 mg who were down-titrated to 1800 mg/day were in-
cluded in the 2400-mg group for all analyses.. .Of the 111 patients in the 2400-
mg group with analyzable seizure data, 26 were patients in whom SPN-804
was downtitrated to 1800 mg/day.”
Comment: although intention-to-treat analysis was performed and attrition
was reported, the strict intention-to-treat criteria do not comply with the 'once
randomized, always analysed' mantra. Criteria led to the exclusion of 7.9% of
the original randomised population from the analyses. The study also had a
high attrition rate of 32.2%. Furthermore, data in this study from participants
French 2014  (Continued)
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receiving 1800 mg/d was categorised under the 2400 mg/d treatment group
after they were down-titrated. This therefore provides unreliable and mislead-
ing data regarding the tolerance and efficacy of OXC at the 2400 mg dose level.
Selective reporting (re-
porting bias)
Low risk Comment: protocol was not provided; however, all outcomes defined in meth-
ods were reported in results.





Randomised, double-blind, PBO-controlled, parallel-group, multi-centre (47 centres, 8 countries: Ar-
gentina, Chile, Uruguay, Australia, New Zealand, Canada, Israel, and USA)
Duration
1. Prospective baseline period (8 weeks)
2. Treatment period with titration (2-week titration, 14-week maintenance period)
3. Optional entry to open label extension
Participants Randomised population
OXC 30 to 46 mg/kg/d: 138
PBO: 129
ITT population
OXC 30 to 46 mg/kg/d: 136
PBO: 128
Safety population
OXC 30 to 46 mg/kg/d: 138
PBO: 129
No. of participants excluded from analyses
OXC 30 to 46 mg/kg/d: 2
PBO: 1
Excluded due to premature discontinuation of treatment and absence of any seizure data
Age (mean and range)
≥ 3 to 17 years
OXC 30 to 46 mg/kg/d: 11 (3 to 17)
PBO: 11 (3 to 17)
Gender, male, n (%)
OXC 30 to 46 mg/kg/d: 70 (51)
PBO: 71 (55)
Glauser 2000 
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Types of seizure: focal seizures (simple, complex, and focal seizures evolving to secondarily general-
ized seizures)
Seizure frequency during baseline (median and range)
OXC 30 to 46 mg/kg/d: 12 (3 to 1470)
PBO: 13 (2 to 554)
Interventions OXC 30 to 46 mg/kg/d (twice daily)
PBO (twice daily)
Outcomes Primary outcome
1. Percentage of reduction from baseline in FOS frequency per 28 days during treatment period
Secondary outcomes
1. Responder rate (≥ 50% reduction from baseline in focal seizure frequency per 28 days during treat-
ment)
2. Percentage change from baseline in secondarily generalized seizure frequency during treatment
Safety and tolerability outcomes
1. Adverse events (AEs)
2. Vital signs
3. ECG tracings
4. Physical and neurologic examination
5. Laboratory tests
Notes Sponsored by Novartis Pharmaceuticals Corporation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "patients were randomized (using a computer-generated schedule)"
Allocation concealment
(selection bias)






Low risk Quote: "OXC and placebo were supplied to study centers as matching tablets
of identical appearance for oral administration."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "...patients or their parents/legal guardians maintained a diary in which
they recorded seizure type and frequency."
Comment: patients and their legal guardian were the efficacy outcome asses-
sors and were adequately blinded by the matching tablets. Study personnel,
including data analysts and statisticians, were also effectively blinded by the
matching tablets.
Glauser 2000  (Continued)
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Unclear risk Comment: modified intention-to-treat analysis performed and attrition report-
ed. The study had a low attrition rate overall; however, the attrition rate was
unevenly distributed between treatment groups.
Selective reporting (re-
porting bias)
Low risk Comment: protocol was not provided; however, all outcomes defined in Meth-
ods were reported in Results section
Other bias Unclear risk Quote: "Median daily dose of OXC administered during the Maintenance Period
of the Double-blind Treatment Phase was 31.4 mg/kg/day (range: 6.4 to 51.4
mg/kg/day)."
Comment: the range of doses, most noticeably the lowest value of the range,
was outside of the target dose (30 to 46 mg/kg/d). The methods did, howev-
er, specify that all doses were permitted if they did not exceed the target ran-





Randomised, double-blind, parallel-group, alternative dose-controlled, single centre (Thailand)
Duration
1. Prospective baseline period (8 weeks)
2. Treatment period with titration (2-week titration, 14-week maintenance period)
3. Optional entry to open label extension
Participants Randomised population
OXC 1200 mg/d: 19
OXC 600 mg/d: 20
Per-protocol population (used for efficacy analysis)
OXC 1200 mg/d: 17
OXC 600 mg/d 18
Safety population
OXC 1200 mg/d: 19
OXC 600 mg/d: 20
No. of participants excluded from analyses
OXC 1200 mg/d: 2
OXC 600 mg/d: 2
Excluded due to loss during follow-up and discontinuation due to AEs
Age (mean and range)
≥ 18 to 65 years
OXC 1200 mg/d: 31.7 ± 6.9
Kraiprab 2005 
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OXC 600 mg/d: 30.4 ± 7.3
Gender, male, n (%):
OXC 1200 mg/d: 8 (42)
OXC 600 mg/d: 12 (60)
Types of seizure
Focal seizures (simple, complex, and focal seizures evolving to secondarily generalised seizures)
Seizure frequency during baseline (median (mean))
OXC 1200 mg/d: 4.0 (7.7)
OXC 600 mg/d: 4.5 (7.6)
Interventions OXC 1200 mg/d (twice daily)
OXC 600 mg/d (twice daily)
Outcomes Primary outcome
1. Percentage reduction from baseline in FOS frequency per 28 days during treatment period.
Secondary outcomes
1. Responder rate (≥ 50% reduction from baseline in focal seizure frequency per 28 days during treat-
ment).
Safety and tolerability outcomes
1. Adverse events (AEs)
2. Physical and neurologic examination
3. Vital signs
4. Laboratory tests
Notes Sponsored by Novartis Pharmaceuticals Corporation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no information was provided about how patients were randomised
Allocation concealment
(selection bias)





Low risk Quote: "Both medications were dispensed as identical appearing capsules."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The frequency and seizure patterns of each patient were recorded by
the patients themselves or by caregivers in a diary issued by the investigators"
Comment: patients and caregivers therefore acted as the efficacy outcome as-
sessors and were effectively blinded by identical capsules. Study personnel, in-
Kraiprab 2005  (Continued)
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Low risk Comment: intention-to-treat analysis was performed for the safety analysis
but 'per protocol' was used for the efficacy analysis. 'Per protocol' only led to




Low risk Comment: protocol was not provided; however, all outcomes defined in Meth-
ods were reported in Results section





Randomised, double-blind, parallel-group, placebo-controlled, multi-centre (multiple centres, Japan)
Duration
1. Prospective baseline period (8 weeks)
2. Treatment period with titration (2-week titration, 6-week maintenance period)
3. Follow-up period (3 to 5 weeks)
Participants Randomised population
OXC 60 mg/ml: 48
PBO: 51
ITT population
OXC 60 mg/ml: 47
PBO: 51
Safety population
OXC 60 mg/ml: 47
PBO: 51
No. of participants excluded from analyses
OXC 60 mg/ml: 1
Excluded due to not receiving study drug
Age (mean ± SD)
≥ 4 to 14 years
OXC 60 mg/ml: 9.8 (2.91)
PBO: 9.2 (2.83)
Gender, male, n (%)
OXC 60 mg/ml: 26 (54.2)
NCT00975715 
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PBO: 27 (52.9)
Types of seizure
Focal seizures (simple, complex, and focal seizures evolving to secondarily generalized seizures)
Seizure frequency during baseline (median and range)
OXC 60 mg/ml: not provided
PBO: not provided
Interventions OXC 60 mg/ml oral suspension doses, based on body weight (twice daily)
PBO oral suspension doses, based on body weight (twice daily)
Outcomes Primary outcome
1. Percentage of reduction from baseline in FOS frequency per 28 days during treatment period.
Secondary outcomes
1. FOS frequency per 28 days, by study period (every 28 days) and treatment group
2. Responder rate (≥ 50% reduction in FOS frequency per 28 days from baseline)
3. Percent change in FOS frequency during treatment
4. Number of participants with Clinical Global Impression of Change (CGIC)
Safety and tolerability outcomes
1. Adverse events (AEs)
Notes Sponsored by Novartis Pharmaceuticals
Trial registration number: NCT00975715
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk Comment: no protocol provided. Information about blinding unavailable
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Quote: "The Full Analysis set included all participants who received study
drug."
NCT00975715  (Continued)
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Comment: attrition reported and modified intention-to-treat performed. The
study had a low attrition rate overall; however, the attrition rate was unevenly
distributed between treatment groups.
Selective reporting (re-
porting bias)
Low risk Comment: no protocol provided; however, all outcomes defined on the study
details tab of the clinicaltrials.gov webpage were subsequently reported on
the results tab.
Other bias Unclear risk Comment: publication is not available so it is not possible to ascertain or dis-





Randomised, rater-blind, parallel-group, multi-centre (56 centres, 7 countries: USA, Argentina, France,
Germany, Brazil, Mexico, and Lithuania)
Duration
1. Screening period (72 hours)
2. Baseline period (24 to 72 hours)
3. Treatment period for low dose (10 mg/kg/d) OXC group (9-day maintenance only) or high dose (60
mg/kg/d) OXC group (26-day titration period + 9 days' maintenance)
4. Open-label extensions (6 months)
Participants Randomised population
OXC 60 mg/kg/d: 64
OXC 10 mg/kg/d: 64
Modified ITT population
OXC 60 mg/kg/d: 59
OXC 10 mg/kg/d: 57
Safety population
OXC 60 mg/kg/d: 64
OXC 10 mg/kg/d: 64
No. of participants excluded from analyses
OXC 60 mg/kg/d: 5
OXC 10 mg/kg/d: 7
Excluded due to having no video-EEG data available.
Age
≥ 1 month to < 4 years
Gender, male, n (%)
OXC 60 mg/kg/d: 38 (59)
Pina-Garza 2005 
Oxcarbazepine add-on for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
OXC 10 mg/kg/d: 35 (55)
Types of seizure
Focal seizures (simple, complex, and focal seizures evolving to secondarily generalized seizures)
Seizure frequency during baseline (median (mean))
OXC 60 mg/kg/d: 3.83 (10.82)
OXC 10 mg/kg/d: 7.00 (14.03)
Interventions OXC 60 mg/kg/d (high dose)
OXC 10 mg/kg/d (low dose)
Outcomes Primary outcome
1. Absolute change in type 1 seizure frequency from baseline per 24 hours during the last 72 hours of
continuous video-EEG monitoring in the treatment phase.
Secondary outcomes
1. Percentage change in type 1 seizure frequency per 24 hours.
2. The absolute change in type 1 and type 2 seizure frequency per 24 hours (a type 2 seizure was elec-
trographically similar to a type 1 seizure without the clinical correlate).
3. Response to treatment (characterized by at least a 50%, 75%, or 100% reduction in type 1 seizure fre-
quency per 24 hours).
Safety and tolerability outcomes
1. Adverse events (AEs) and serious adverse events (SAEs).
Notes Sponsored by Novartis Pharmaceuticals Inc.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was performed using a validated system (interactive
voice response system) that automated the random assignment of treatment
groups and age strata."
Allocation concealment
(selection bias)






Low risk Comment: participants were not blinded; however, all participants were un-
der 4 years of age so likelihood of this having an impact on efficacy outcomes
is low. The study instead used a rater-blind design.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "...seizures were assessed and recorded by an independent pediatric





Low risk Comment: attrition was reported and was even between treatment groups. A
modified intention-to-treat population was used for efficacy analyses.
Pina-Garza 2005  (Continued)
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Selective reporting (re-
porting bias)
Low risk Comment: protocol was not provided; however, all outcomes defined in Meth-
ods were reported in Results section
Other bias High risk Comment: the duration of the treatment period was significantly different for
the 2 treatment groups.
Quote: “The treatment phase lasted 9 days for the low-dose group and 35 days
for the high-dose group.”
Pina-Garza 2005  (Continued)
AEs: Adverse eIects; EEG: Electroencephalogram; FOS: Focal-onset seizures; OXC: Oxcarbazepine; PBO: Placebo
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
EUCTR2004-002260-25-AT No data available and we suspect that the study included a proportion of participants who re-
ceived oxcarbazepine as a monotherapy rather than as an adjunctive therapy.
EUCTR2006-003834-14-DE Terminated early due to low recruitment. No data available.
EUCTR2008-003334-19-BG Open-label extension study with single-group assignment.
Glauser 2001 Open-label extension study with single-group assignment.
Houtkooper 1987 Oxcarbazepine was used as a replacement for carbamazepine rather than as an adjunctive to sta-
ble anti-epileptic medication. The study included participants with generalised-onset seizures. Da-
ta were not reported separately for participants with focal versus generalised epilepsy, therefore it
was not possible to extract the relevant data to permit inclusion.
Kutluay 2003 A meta-analysis of safety data taken from 21 studies.
McKee 1994 The study investigated the pharmacokinetics of oxcarbazepine and initially used oxcarbazepine as
a monotherapy rather than as an adjunctive therapy.
NCT00050947 Oxcarbazepine utilised as a monotherapy.
NCT00391534 Terminated early due to low recruitment. No data available.
NCT00918424 Open-label extension study with single-group assignment.
NCT01891890 Oxcarbazepine utilised as a monotherapy.
Rey 2004 The study investigated the pharmacokinetics of oxcarbazepine and therefore consisted of irrele-
vant outcomes.
Steinhoff 2012 Terminated early due to low recruitment. No data available.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Study design
Randomised, open-label (no blinding), active-controlled, parallel-group, multi-centre.
CTRI/2010/091/000100 
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Duration
1. No information regarding baseline period
2. treatment period with titration (4 weeks up-titration, up to 12 weeks' maintenance)
Participants Randomised population: 210 participants
Age (range): ≥ 18 to 65 years
Gender: male and female
Types of seizure: drug-resistant epilepsy suffering from focal-onset seizures with or without sec-
ondary generalisation
Seizure frequency during baseline: at least 1 seizure in the past month
Interventions OXC 1200 mg/d
Eslicarbazepine Acetate 1200 mg/d
Outcomes Primary outcome
1. Median percentage reduction in frequency of seizures compared to baseline
Secondary outcomes
1. Responder rate (defined as proportion of patients with a minimum of 50% reduction in seizure
frequency from baseline)
2. Number of seizure-free patients during the treatment period
3. Change in QOLIE-31 score
4. Physician's and patient's global assessment to the treatment
Notes We requested data from the principal investigator and primary contact person; however, no corre-





Randomised, open-label (no blinding), active-controlled, parallel-group, multi-centre
Duration
1. No information regarding baseline period
2. 12 week treatment period
Participants Randomised population: 200 participants
Age (range): ≥ 18 to 65 years
Gender: male and female
Types of seizure: simple or complex focal seizures with or without secondary generalization and
taking stable doses of antiepileptic drugs.
CTRI/2010/091/001194 
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Seizure frequency during baseline: at least 2 seizures in the past month or at least 4 seizures in
the past 2 months.
Interventions OXC 600 mg/d (twice daily)
Eslicarbazepine 400 mg/d (once daily)
Outcomes Primary outcome
1. ≥ 50% reduction in seizure frequency in the treatment period relative to baseline
Secondary outcomes
1. Seizure frequency per 4 weeks
2. Number of days with seizures
3. Proportion of seizure free subjects
4. Proportion of subjects with an exacerbation in seizure frequency (≥ 25%)
5. Distribution of seizure reduction (proportion of subjects with seizure reduction of 50%; ≥ 50% to
75%, or > 75%)
6. Subjects' global assessment for efficacy
7. Physicians' global assessment for efficacy
Notes We requested data from the principal investigator and primary contact person; however, no corre-





Randomised, open-label (no blinding), active-controlled, parallel-group, multi-centre
Duration
1. 13-week study (do not specify duration of baseline or treatment period)
Participants Randomised population: 270 participants
Age (range): ≥ 18 to 65 years
Gender: male and female
Types of seizure: simple or complex focal seizures with or without secondary generalisation and
taking stable doses of antiepileptic drugs.
Seizure frequency during baseline: at least 2 focal seizures in the past 4 weeks
Interventions OXC 300 - 900 mg/d
IN-AQUL-002 (no information on dosage)
Outcomes Primary outcome
1. Change in the seizure frequency rate
Secondary outcomes
CTRI/2010/091/006085 
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1. Responder rate
2. Change in number of seizure-free days
Notes We requested data from the principal investigator and primary contact person; however, no corre-





D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Oxcarbazepine vs. control





Statistical method Effect size
1 50% or greater reduction
in seizure frequency
6 1593 Risk Ratio (M-H, Random, 95% CI) 1.80 [1.27, 2.56]
2 Ataxia 5 1227 Risk Ratio (M-H, Random, 99% CI) 2.54 [0.86, 7.54]
3 Dizziness 4 1366 Risk Ratio (M-H, Fixed, 99% CI) 2.58 [1.81, 3.68]
4 Fatigue 4 1366 Risk Ratio (M-H, Fixed, 99% CI) 1.88 [1.07, 3.32]
5 Nausea 5 1464 Risk Ratio (M-H, Random, 99% CI) 1.87 [0.77, 4.56]
6 Somnolence 6 1593 Risk Ratio (M-H, Random, 99% CI) 2.03 [1.17, 3.54]
7 Headache 4 1366 Risk Ratio (M-H, Fixed, 99% CI) 1.27 [0.94, 1.71]
8 Hyponatraemia 6 1593 Risk Ratio (M-H, Fixed, 99% CI) 2.53 [0.27, 23.85]
9 Vertigo 2 793 Risk Ratio (M-H, Fixed, 99% CI) 4.62 [1.32, 16.13]
10 Diplopia 5 1465 Risk Ratio (M-H, Fixed, 99% CI) 5.50 [2.83, 10.68]
11 Rash 3 405 Risk Ratio (M-H, Fixed, 99% CI) 1.22 [0.38, 3.85]
12 Tremor 1 694 Risk Ratio (M-H, Fixed, 99% CI) 2.13 [0.77, 5.93]
13 Pyrexia 3 524 Risk Ratio (M-H, Fixed, 99% CI) 1.29 [0.71, 2.36]
14 Abnormal gait 2 961 Risk Ratio (M-H, Fixed, 99% CI) 5.53 [1.74, 17.61]
15 Abdominal pain 2 961 Risk Ratio (M-H, Random, 99% CI) 1.37 [0.42, 4.52]
16 Nystagmus 2 961 Risk Ratio (M-H, Fixed, 99% CI) 4.56 [1.90, 10.94]
17 Viral infection 2 961 Risk Ratio (M-H, Random, 99% CI) 2.22 [0.06, 79.48]
18 Vomiting 6 1593 Risk Ratio (M-H, Random, 99% CI) 2.55 [1.20, 5.42]
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Statistical method Effect size
19 Abnormal vision 3 1000 Risk Ratio (M-H, Random, 99% CI) 2.77 [0.59, 13.00]
20 Upper respiratory tract
infection
2 366 Risk Ratio (M-H, Fixed, 99% CI) 0.68 [0.29, 1.59]
21 Seizure freedom 5 1494 Risk Ratio (M-H, Random, 95% CI) 2.86 [1.19, 6.87]
22 Treatment withdrawal 6 1593 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.44, 2.13]
 
 
Analysis 1.1.   Comparison 1 Oxcarbazepine vs. control, Outcome 1 50% or greater reduction in seizure frequency.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Barcs 2000 205/521 22/173 19.7% 3.09[2.06,4.64]
French 2014 94/245 34/121 21.72% 1.37[0.99,1.89]
Glauser 2000 55/138 28/129 20.17% 1.84[1.25,2.7]
Kraiprab 2005 9/19 8/20 12.59% 1.18[0.58,2.42]
NCT00975715 11/48 2/51 4.73% 5.84[1.37,25.02]
Pina-Garza 2005 38/64 27/64 21.08% 1.41[0.99,2]
   
Total (95% CI) 1035 558 100% 1.8[1.27,2.56]
Total events: 412 (Oxcarbazepine), 121 (Control)  
Heterogeneity: Tau2=0.12; Chi2=16.51, df=5(P=0.01); I2=69.71%  
Test for overall effect: Z=3.31(P=0)  
Favours control 200.05 50.2 1 Favours oxcarbazepine
 
 
Analysis 1.2.   Comparison 1 Oxcarbazepine vs. control, Outcome 2 Ataxia.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 103/521 9/173 32.48% 3.8[1.6,9.04]
Glauser 2000 19/138 6/129 27.86% 2.96[0.92,9.48]
Kraiprab 2005 5/19 7/20 26.38% 0.75[0.21,2.66]
NCT00975715 2/48 0/51 6.38% 5.31[0.1,277.61]
Pina-Garza 2005 5/64 0/64 6.9% 11[0.25,480.93]
   
Total (99% CI) 790 437 100% 2.54[0.86,7.54]
Total events: 134 (Oxcarbazepine), 22 (Control)  
Heterogeneity: Tau2=0.44; Chi2=9.41, df=4(P=0.05); I2=57.51%  
Test for overall effect: Z=2.21(P=0.03)  
Favours oxcarbazepine 10000.001 100.1 1 Favours control
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Analysis 1.3.   Comparison 1 Oxcarbazepine vs. control, Outcome 3 Dizziness.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 172/521 22/173 46.93% 2.6[1.52,4.44]
French 2014 74/245 18/121 34.24% 2.03[1.1,3.75]
Glauser 2000 40/138 10/129 14.69% 3.74[1.59,8.79]
Kraiprab 2005 8/19 3/20 4.15% 2.81[0.6,13.04]
   
Total (99% CI) 923 443 100% 2.58[1.81,3.68]
Total events: 294 (Oxcarbazepine), 53 (Control)  
Heterogeneity: Tau2=0; Chi2=2.28, df=3(P=0.52); I2=0%  
Test for overall effect: Z=6.87(P<0.0001)  
Favours oxcarbazepine 200.05 50.2 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Oxcarbazepine vs. control, Outcome 4 Fatigue.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 72/521 12/173 55.14% 1.99[0.92,4.31]
French 2014 11/245 1/121 4.1% 5.43[0.37,78.85]
Glauser 2000 18/138 11/129 34.8% 1.53[0.6,3.89]
Kraiprab 2005 1/19 2/20 5.96% 0.53[0.03,11.06]
   
Total (99% CI) 923 443 100% 1.88[1.07,3.32]
Total events: 102 (Oxcarbazepine), 26 (Control)  
Heterogeneity: Tau2=0; Chi2=2.57, df=3(P=0.46); I2=0%  
Test for overall effect: Z=2.88(P=0)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.5.   Comparison 1 Oxcarbazepine vs. control, Outcome 5 Nausea.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 117/521 14/173 30.38% 2.78[1.39,5.55]
French 2014 29/245 14/121 28.81% 1.02[0.47,2.25]
Glauser 2000 30/138 7/129 24.75% 4.01[1.42,11.27]
Kraiprab 2005 1/19 1/20 5.36% 1.05[0.03,36.58]
NCT00975715 2/47 3/51 10.69% 0.72[0.07,7.16]
   
Total (99% CI) 970 494 100% 1.87[0.77,4.56]
Total events: 179 (Oxcarbazepine), 39 (Control)  
Heterogeneity: Tau2=0.32; Chi2=10.98, df=4(P=0.03); I2=63.56%  
Test for overall effect: Z=1.82(P=0.07)  
Favours oxcarbazepine 500.02 100.1 1 Favours control
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Analysis 1.6.   Comparison 1 Oxcarbazepine vs. control, Outcome 6 Somnolence.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 137/521 20/173 22.79% 2.27[1.28,4.04]
French 2014 31/245 11/121 17.54% 1.39[0.59,3.28]
Glauser 2000 48/138 18/129 21.55% 2.49[1.32,4.72]
Kraiprab 2005 8/19 10/20 16.81% 0.84[0.34,2.07]
NCT00975715 20/48 5/51 12.79% 4.25[1.31,13.82]
Pina-Garza 2005 11/64 3/64 8.51% 3.67[0.73,18.43]
   
Total (99% CI) 1035 558 100% 2.03[1.17,3.54]
Total events: 255 (Oxcarbazepine), 67 (Control)  
Heterogeneity: Tau2=0.15; Chi2=12.29, df=5(P=0.03); I2=59.3%  
Test for overall effect: Z=3.28(P=0)  
Favours oxcarbazepine 200.05 50.2 1 Favours control
 
 
Analysis 1.7.   Comparison 1 Oxcarbazepine vs. control, Outcome 7 Headache.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 142/521 41/173 57.53% 1.15[0.77,1.71]
French 2014 29/245 14/121 17.52% 1.02[0.47,2.25]
Glauser 2000 44/138 23/129 22.22% 1.79[1,3.2]
Kraiprab 2005 3/19 3/20 2.73% 1.05[0.15,7.28]
   
Total (99% CI) 923 443 100% 1.27[0.94,1.71]
Total events: 218 (Oxcarbazepine), 81 (Control)  
Heterogeneity: Tau2=0; Chi2=3.26, df=3(P=0.35); I2=8.09%  
Test for overall effect: Z=2.05(P=0.04)  
Favours oxcarbazepine 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.8.   Comparison 1 Oxcarbazepine vs. control, Outcome 8 Hyponatraemia.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 2/521 0/173 39.4% 1.67[0.03,89.56]
French 2014 1/245 0/121 35.12% 1.49[0.02,98.88]
Glauser 2000 0/138 0/129   Not estimable
Kraiprab 2005 0/19 0/20   Not estimable
NCT00975715 2/48 0/51 25.49% 5.31[0.1,277.61]
Pina-Garza 2005 0/64 0/64   Not estimable
   
Total (99% CI) 1035 558 100% 2.53[0.27,23.85]
Total events: 5 (Oxcarbazepine), 0 (Control)  
Heterogeneity: Tau2=0; Chi2=0.41, df=2(P=0.81); I2=0%  
Test for overall effect: Z=1.07(P=0.29)  
Favours oxcarbazepine 2000.005 100.1 1 Favours control
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Analysis 1.9.   Comparison 1 Oxcarbazepine vs. control, Outcome 9 Vertigo.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 55/521 4/173 92.53% 4.57[1.23,17]
NCT00975715 2/48 0/51 7.47% 5.31[0.1,277.61]
   
Total (99% CI) 569 224 100% 4.62[1.32,16.13]
Total events: 57 (Oxcarbazepine), 4 (Control)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.93); I2=0%  
Test for overall effect: Z=3.15(P=0)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.10.   Comparison 1 Oxcarbazepine vs. control, Outcome 10 Diplopia.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 145/521 8/173 56.66% 6.02[2.43,14.92]
French 2014 28/245 5/121 31.58% 2.77[0.82,9.34]
Glauser 2000 23/138 1/129 4.88% 21.5[1.58,293.04]
Kraiprab 2005 1/19 1/20 4.6% 1.05[0.03,36.58]
NCT00975715 2/48 0/51 2.29% 5.31[0.1,277.61]
   
Total (99% CI) 971 494 100% 5.5[2.83,10.68]
Total events: 199 (Oxcarbazepine), 15 (Control)  
Heterogeneity: Tau2=0; Chi2=5.43, df=4(P=0.25); I2=26.35%  
Test for overall effect: Z=6.62(P<0.0001)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.11.   Comparison 1 Oxcarbazepine vs. control, Outcome 11 Rash.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Glauser 2000 5/138 6/129 71.87% 0.78[0.17,3.59]
Kraiprab 2005 1/19 0/20 5.65% 3.15[0.05,195.59]
NCT00975715 4/48 2/51 22.47% 2.13[0.24,18.61]
   
Total (99% CI) 205 200 100% 1.22[0.38,3.85]
Total events: 10 (Oxcarbazepine), 8 (Control)  
Heterogeneity: Tau2=0; Chi2=1.36, df=2(P=0.51); I2=0%  
Test for overall effect: Z=0.44(P=0.66)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
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Analysis 1.12.   Comparison 1 Oxcarbazepine vs. control, Outcome 12 Tremor.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 45/521 7/173 100% 2.13[0.77,5.93]
   
Total (99% CI) 521 173 100% 2.13[0.77,5.93]
Total events: 45 (Oxcarbazepine), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.13.   Comparison 1 Oxcarbazepine vs. control, Outcome 13 Pyrexia.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Glauser 2000 21/138 20/129 75.25% 0.98[0.47,2.06]
NCT00975715 2/48 2/51 7.06% 1.06[0.09,13.25]
Pina-Garza 2005 11/64 6/94 17.69% 2.69[0.78,9.29]
   
Total (99% CI) 250 274 100% 1.29[0.71,2.36]
Total events: 34 (Oxcarbazepine), 28 (Control)  
Heterogeneity: Tau2=0; Chi2=3.28, df=2(P=0.19); I2=39.11%  
Test for overall effect: Z=1.09(P=0.28)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.14.   Comparison 1 Oxcarbazepine vs. control, Outcome 14 Abnormal gait.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 52/521 2/173 42.07% 8.63[1.37,54.48]
Glauser 2000 14/138 4/129 57.93% 3.27[0.79,13.62]
   
Total (99% CI) 659 302 100% 5.53[1.74,17.61]
Total events: 66 (Oxcarbazepine), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=1.29, df=1(P=0.26); I2=22.25%  
Test for overall effect: Z=3.8(P=0)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.15.   Comparison 1 Oxcarbazepine vs. control, Outcome 15 Abdominal pain.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 52/521 8/173 50.51% 2.16[0.83,5.59]
Glauser 2000 12/138 13/129 49.49% 0.86[0.32,2.3]
   
Total (99% CI) 659 302 100% 1.37[0.42,4.52]
Favours oxcarbazepine 50.2 20.5 1 Favours control
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Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Total events: 64 (Oxcarbazepine), 21 (Control)  
Heterogeneity: Tau2=0.29; Chi2=3.04, df=1(P=0.08); I2=67.1%  
Test for overall effect: Z=0.68(P=0.5)  
Favours oxcarbazepine 50.2 20.5 1 Favours control
 
 
Analysis 1.16.   Comparison 1 Oxcarbazepine vs. control, Outcome 16 Nystagmus.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Barcs 2000 88/521 7/173 83.56% 4.17[1.56,11.19]
Glauser 2000 14/138 2/129 16.44% 6.54[0.96,44.7]
   
Total (99% CI) 659 302 100% 4.56[1.9,10.94]
Total events: 102 (Oxcarbazepine), 9 (Control)  
Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%  
Test for overall effect: Z=4.47(P<0.0001)  
Favours control 1000.01 100.1 1 Favours oxcarbazepine
 
 
Analysis 1.17.   Comparison 1 Oxcarbazepine vs. control, Outcome 17 Viral infection.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 47/521 24/173 53.11% 0.65[0.35,1.19]
Glauser 2000 19/138 2/129 46.89% 8.88[1.34,58.71]
   
Total (99% CI) 659 302 100% 2.22[0.06,79.48]
Total events: 66 (Oxcarbazepine), 26 (Control)  
Heterogeneity: Tau2=3.58; Chi2=13.08, df=1(P=0); I2=92.36%  
Test for overall effect: Z=0.57(P=0.57)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.18.   Comparison 1 Oxcarbazepine vs. control, Outcome 18 Vomiting.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 124/521 8/173 24.09% 5.15[2.07,12.81]
French 2014 26/245 11/121 24.67% 1.17[0.48,2.82]
Glauser 2000 50/138 19/129 29.76% 2.46[1.33,4.57]
Kraiprab 2005 2/19 0/20 3.38% 5.25[0.11,261.57]
NCT00975715 5/48 3/51 11.84% 1.77[0.29,10.8]
Pina-Garza 2005 6/64 1/64 6.27% 6[0.39,93.36]
   
Total (99% CI) 1035 558 100% 2.55[1.2,5.42]
Total events: 213 (Oxcarbazepine), 42 (Control)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
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Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Heterogeneity: Tau2=0.23; Chi2=10.82, df=5(P=0.06); I2=53.8%  
Test for overall effect: Z=3.2(P=0)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.19.   Comparison 1 Oxcarbazepine vs. control, Outcome 19 Abnormal vision.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 99% CI   M-H, Random, 99% CI
Barcs 2000 65/521 7/173 41.38% 3.08[1.13,8.38]
Glauser 2000 19/138 2/129 28.63% 8.88[1.34,58.71]
Kraiprab 2005 3/19 4/20 29.99% 0.79[0.13,4.71]
   
Total (99% CI) 678 322 100% 2.77[0.59,13]
Total events: 87 (Oxcarbazepine), 13 (Control)  
Heterogeneity: Tau2=0.72; Chi2=6.08, df=2(P=0.05); I2=67.1%  
Test for overall effect: Z=1.7(P=0.09)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Analysis 1.20.   Comparison 1 Oxcarbazepine vs. control, Outcome 20 Upper respiratory tract infection.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Glauser 2000 10/138 15/129 76.18% 0.62[0.23,1.7]
NCT00975715 4/48 5/51 23.82% 0.85[0.16,4.42]
   
Total (99% CI) 186 180 100% 0.68[0.29,1.59]
Total events: 14 (Oxcarbazepine), 20 (Control)  
Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Favours oxcarbazepine 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.21.   Comparison 1 Oxcarbazepine vs. control, Outcome 21 Seizure freedom.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Barcs 2000 61/521 1/173 13.47% 20.26[2.83,145.02]
French 2014 20/245 4/121 26.27% 2.47[0.86,7.07]
Glauser 2000 5/138 1/129 12.04% 4.67[0.55,39.47]
Kraiprab 2005 2/19 2/20 14.57% 1.05[0.16,6.74]
Pina-Garza 2005 19/64 10/64 33.65% 1.9[0.96,3.76]
   
Total (95% CI) 987 507 100% 2.86[1.19,6.87]
Total events: 107 (Oxcarbazepine), 18 (Control)  
Heterogeneity: Tau2=0.47; Chi2=8.25, df=4(P=0.08); I2=51.49%  
Favours control 2000.005 100.1 1 Favours oxcarbazepine
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Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=2.36(P=0.02)  
Favours control 2000.005 100.1 1 Favours oxcarbazepine
 
 
Analysis 1.22.   Comparison 1 Oxcarbazepine vs. control, Outcome 22 Treatment withdrawal.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Barcs 2000 246/521 49/173 58.1% 1.67[1.29,2.15]
French 2014 92/245 26/121 27.49% 1.75[1.2,2.55]
Glauser 2000 21/138 10/129 8.16% 1.96[0.96,4.01]
Kraiprab 2005 1/19 2/20 1.54% 0.53[0.05,5.34]
NCT00975715 9/48 1/51 0.77% 9.56[1.26,72.67]
Pina-Garza 2005 8/64 5/64 3.95% 1.6[0.55,4.63]
   
Total (95% CI) 1035 558 100% 1.75[1.44,2.13]
Total events: 377 (Oxcarbazepine), 93 (Control)  
Heterogeneity: Tau2=0; Chi2=4, df=5(P=0.55); I2=0%  
Test for overall effect: Z=5.61(P<0.0001)  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Comparison 2.   Oxcarbazepine vs. control (Subgroup analysis - Control group)





Statistical method Effect size
1 50% or greater reduction in seizure fre-
quency
6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Placebo 4 1426 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [1.69, 2.59]
1.2 Alternate oxcarbazepine dosage 2 167 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.99, 1.86]
2 Seizure freedom 5   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Placebo 3 1327 Risk Ratio (M-H, Fixed, 95% CI) 6.14 [2.62, 14.41]
2.2 Alternate oxcarbazepine dosage 2 167 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [0.93, 3.33]
3 Treatment withdrawal 6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Placebo 4 1426 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.46, 2.18]
3.2 Alternate oxcarbazepine dosage 2 167 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.51, 3.34]
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Analysis 2.1.   Comparison 2 Oxcarbazepine vs. control (Subgroup analysis
- Control group), Outcome 1 50% or greater reduction in seizure frequency.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.1.1 Placebo  
Barcs 2000 205/521 22/173 30.18% 3.09[2.06,4.64]
French 2014 94/245 34/121 41.6% 1.37[0.99,1.89]
Glauser 2000 55/138 28/129 26.45% 1.84[1.25,2.7]
NCT00975715 11/48 2/51 1.77% 5.84[1.37,25.02]
Subtotal (95% CI) 952 474 100% 2.09[1.69,2.59]
Total events: 365 (Oxcarbazepine), 86 (Control)  
Heterogeneity: Tau2=0; Chi2=12.51, df=3(P=0.01); I2=76.02%  
Test for overall effect: Z=6.81(P<0.0001)  
   
2.1.2 Alternate oxcarbazepine dosage  
Kraiprab 2005 9/19 8/20 22.4% 1.18[0.58,2.42]
Pina-Garza 2005 38/64 27/64 77.6% 1.41[0.99,2]
Subtotal (95% CI) 83 84 100% 1.36[0.99,1.86]
Total events: 47 (Oxcarbazepine), 35 (Control)  
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=1.9(P=0.06)  
Test for subgroup differences: Chi2=4.96, df=1 (P=0.03), I2=79.84%  
Favours control 200.05 50.2 1 Favours oxcarbazepine
 
 
Analysis 2.2.   Comparison 2 Oxcarbazepine vs. control (Subgroup
analysis - Control group), Outcome 2 Seizure freedom.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.2.1 Placebo  
Barcs 2000 61/521 1/173 19.03% 20.26[2.83,145.02]
French 2014 20/245 4/121 67.87% 2.47[0.86,7.07]
Glauser 2000 5/138 1/129 13.1% 4.67[0.55,39.47]
Subtotal (95% CI) 904 423 100% 6.14[2.62,14.41]
Total events: 86 (Oxcarbazepine), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=4.36, df=2(P=0.11); I2=54.14%  
Test for overall effect: Z=4.17(P<0.0001)  
   
2.2.2 Alternate oxcarbazepine dosage  
Kraiprab 2005 2/19 2/20 16.31% 1.05[0.16,6.74]
Pina-Garza 2005 19/64 10/64 83.69% 1.9[0.96,3.76]
Subtotal (95% CI) 83 84 100% 1.76[0.93,3.33]
Total events: 21 (Oxcarbazepine), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
Test for subgroup differences: Chi2=5.29, df=1 (P=0.02), I2=81.08%  
Favours control 2000.005 100.1 1 Favours oxcarbazepine
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Analysis 2.3.   Comparison 2 Oxcarbazepine vs. control (Subgroup
analysis - Control group), Outcome 3 Treatment withdrawal.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.3.1 Placebo  
Barcs 2000 246/521 49/173 61.47% 1.67[1.29,2.15]
French 2014 92/245 26/121 29.08% 1.75[1.2,2.55]
Glauser 2000 21/138 10/129 8.64% 1.96[0.96,4.01]
NCT00975715 9/48 1/51 0.81% 9.56[1.26,72.67]
Subtotal (95% CI) 952 474 100% 1.78[1.46,2.18]
Total events: 368 (Oxcarbazepine), 86 (Control)  
Heterogeneity: Tau2=0; Chi2=2.98, df=3(P=0.4); I2=0%  
Test for overall effect: Z=5.63(P<0.0001)  
   
2.3.2 Alternate oxcarbazepine dosage  
Kraiprab 2005 1/19 2/20 28.04% 0.53[0.05,5.34]
Pina-Garza 2005 8/64 5/64 71.96% 1.6[0.55,4.63]
Subtotal (95% CI) 83 84 100% 1.3[0.51,3.34]
Total events: 9 (Oxcarbazepine), 7 (Control)  
Heterogeneity: Tau2=0; Chi2=0.73, df=1(P=0.39); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=0.41, df=1 (P=0.52), I2=0%  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Comparison 3.   Oxcarbazepine vs. control (Subgroup analysis - Age group)





Statistical method Effect size
1 50% or greater reduction in
seizure frequency
6 1593 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.60, 2.29]
1.1 Adults 3 1099 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [1.58, 2.57]
1.2 Children 3 494 Risk Ratio (M-H, Fixed, 95% CI) 1.77 [1.36, 2.30]
2 Seizure freedom 5 1494 Risk Ratio (M-H, Fixed, 95% CI) 3.50 [2.07, 5.92]
2.1 Adults 3 1099 Risk Ratio (M-H, Fixed, 95% CI) 5.19 [2.29, 11.75]
2.2 Children 2 395 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [1.13, 4.14]
3 Treatment withdrawal 6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Adults 3 1099 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.36, 2.06]
3.2 Children 3 494 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [1.32, 4.01]
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Analysis 3.1.   Comparison 3 Oxcarbazepine vs. control (Subgroup analysis
- Age group), Outcome 1 50% or greater reduction in seizure frequency.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.1.1 Adults  
Barcs 2000 205/521 22/173 22.9% 3.09[2.06,4.64]
French 2014 94/245 34/121 31.56% 1.37[0.99,1.89]
Kraiprab 2005 9/19 8/20 5.4% 1.18[0.58,2.42]
Subtotal (95% CI) 785 314 59.87% 2.01[1.58,2.57]
Total events: 308 (Oxcarbazepine), 64 (Control)  
Heterogeneity: Tau2=0; Chi2=11.86, df=2(P=0); I2=83.14%  
Test for overall effect: Z=5.61(P<0.0001)  
   
3.1.2 Children  
Glauser 2000 55/138 28/129 20.07% 1.84[1.25,2.7]
NCT00975715 11/48 2/51 1.34% 5.84[1.37,25.02]
Pina-Garza 2005 38/64 27/64 18.72% 1.41[0.99,2]
Subtotal (95% CI) 250 244 40.13% 1.77[1.36,2.3]
Total events: 104 (Oxcarbazepine), 57 (Control)  
Heterogeneity: Tau2=0; Chi2=4.27, df=2(P=0.12); I2=53.11%  
Test for overall effect: Z=4.3(P<0.0001)  
   
Total (95% CI) 1035 558 100% 1.91[1.6,2.29]
Total events: 412 (Oxcarbazepine), 121 (Control)  
Heterogeneity: Tau2=0; Chi2=16.51, df=5(P=0.01); I2=69.71%  
Test for overall effect: Z=7.06(P<0.0001)  
Test for subgroup differences: Chi2=0.49, df=1 (P=0.49), I2=0%  
Favours control 200.05 50.2 1 Favours oxcarbazepine
 
 
Analysis 3.2.   Comparison 3 Oxcarbazepine vs. control (Subgroup analysis - Age group), Outcome 2 Seizure freedom.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.2.1 Adults  
Barcs 2000 61/521 1/173 7.57% 20.26[2.83,145.02]
French 2014 20/245 4/121 26.99% 2.47[0.86,7.07]
Kraiprab 2005 2/19 2/20 9.82% 1.05[0.16,6.74]
Subtotal (95% CI) 785 314 44.38% 5.19[2.29,11.75]
Total events: 83 (Oxcarbazepine), 7 (Control)  
Heterogeneity: Tau2=0; Chi2=6.59, df=2(P=0.04); I2=69.66%  
Test for overall effect: Z=3.95(P<0.0001)  
   
3.2.2 Children  
Glauser 2000 5/138 1/129 5.21% 4.67[0.55,39.47]
Pina-Garza 2005 19/64 10/64 50.41% 1.9[0.96,3.76]
Subtotal (95% CI) 202 193 55.62% 2.16[1.13,4.14]
Total events: 24 (Oxcarbazepine), 11 (Control)  
Heterogeneity: Tau2=0; Chi2=0.64, df=1(P=0.42); I2=0%  
Test for overall effect: Z=2.32(P=0.02)  
   
Total (95% CI) 987 507 100% 3.5[2.07,5.92]
Favours control 2000.005 100.1 1 Favours oxcarbazepine
Oxcarbazepine add-on for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 107 (Oxcarbazepine), 18 (Control)  
Heterogeneity: Tau2=0; Chi2=8.25, df=4(P=0.08); I2=51.49%  
Test for overall effect: Z=4.68(P<0.0001)  
Test for subgroup differences: Chi2=2.7, df=1 (P=0.1), I2=62.99%  
Favours control 2000.005 100.1 1 Favours oxcarbazepine
 
 
Analysis 3.3.   Comparison 3 Oxcarbazepine vs. control (Subgroup
analysis - Age group), Outcome 3 Treatment withdrawal.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.3.1 Adults  
Barcs 2000 246/521 49/173 66.68% 1.67[1.29,2.15]
French 2014 92/245 26/121 31.55% 1.75[1.2,2.55]
Kraiprab 2005 1/19 2/20 1.77% 0.53[0.05,5.34]
Subtotal (95% CI) 785 314 100% 1.67[1.36,2.06]
Total events: 339 (Oxcarbazepine), 77 (Control)  
Heterogeneity: Tau2=0; Chi2=1.01, df=2(P=0.6); I2=0%  
Test for overall effect: Z=4.81(P<0.0001)  
   
3.3.2 Children  
Glauser 2000 21/138 10/129 63.39% 1.96[0.96,4.01]
NCT00975715 9/48 1/51 5.95% 9.56[1.26,72.67]
Pina-Garza 2005 8/64 5/64 30.66% 1.6[0.55,4.63]
Subtotal (95% CI) 250 244 100% 2.3[1.32,4.01]
Total events: 38 (Oxcarbazepine), 16 (Control)  
Heterogeneity: Tau2=0; Chi2=2.54, df=2(P=0.28); I2=21.18%  
Test for overall effect: Z=2.94(P=0)  
Test for subgroup differences: Chi2=1.12, df=1 (P=0.29), I2=10.58%  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Comparison 4.   Oxcarbazepine vs. control (Subgroup analysis - Duration of treatment)





Statistical method Effect size
1 50% or greater reduction in
seizure frequency
6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 8 weeks or less 2 227 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.20, 2.41]
1.2 16 weeks 3 672 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.20, 1.92]
1.3 26 weeks 1 694 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [2.06, 4.64]
2 Seizure freedom 5   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Statistical method Effect size
2.1 8 weeks or less 1 128 Risk Ratio (M-H, Fixed, 95% CI) 1.9 [0.96, 3.76]
2.2 16 weeks 3 672 Risk Ratio (M-H, Fixed, 95% CI) 2.41 [1.05, 5.52]
2.3 26 weeks 1 694 Risk Ratio (M-H, Fixed, 95% CI) 20.26 [2.83, 145.02]
3 Treatment withdrawal 6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 8 weeks or less 2 227 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [1.19, 7.06]
3.2 16 weeks 3 672 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [1.26, 2.42]
3.3 26 weeks 1 694 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.29, 2.15]
 
 
Analysis 4.1.   Comparison 4 Oxcarbazepine vs. control (Subgroup analysis -
Duration of treatment), Outcome 1 50% or greater reduction in seizure frequency.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.1.1 8 weeks or less  
NCT00975715 11/48 2/51 6.7% 5.84[1.37,25.02]
Pina-Garza 2005 38/64 27/64 93.3% 1.41[0.99,2]
Subtotal (95% CI) 112 115 100% 1.7[1.2,2.41]
Total events: 49 (Oxcarbazepine), 29 (Control)  
Heterogeneity: Tau2=0; Chi2=3.9, df=1(P=0.05); I2=74.37%  
Test for overall effect: Z=3(P=0)  
   
4.1.2 16 weeks  
French 2014 94/245 34/121 55.34% 1.37[0.99,1.89]
Glauser 2000 55/138 28/129 35.19% 1.84[1.25,2.7]
Kraiprab 2005 9/19 8/20 9.48% 1.18[0.58,2.42]
Subtotal (95% CI) 402 270 100% 1.51[1.2,1.92]
Total events: 158 (Oxcarbazepine), 70 (Control)  
Heterogeneity: Tau2=0; Chi2=1.79, df=2(P=0.41); I2=0%  
Test for overall effect: Z=3.45(P=0)  
   
4.1.3 26 weeks  
Barcs 2000 205/521 22/173 100% 3.09[2.06,4.64]
Subtotal (95% CI) 521 173 100% 3.09[2.06,4.64]
Total events: 205 (Oxcarbazepine), 22 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=5.47(P<0.0001)  
Test for subgroup differences: Chi2=9.05, df=1 (P=0.01), I2=77.89%  
Favours control 200.05 50.2 1 Favours oxcarbazepine
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Analysis 4.2.   Comparison 4 Oxcarbazepine vs. control (Subgroup
analysis - Duration of treatment), Outcome 2 Seizure freedom.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.2.1 8 weeks or less  
Pina-Garza 2005 19/64 10/64 100% 1.9[0.96,3.76]
Subtotal (95% CI) 64 64 100% 1.9[0.96,3.76]
Total events: 19 (Oxcarbazepine), 10 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.84(P=0.07)  
   
4.2.2 16 weeks  
French 2014 20/245 4/121 64.23% 2.47[0.86,7.07]
Glauser 2000 5/138 1/129 12.4% 4.67[0.55,39.47]
Kraiprab 2005 2/19 2/20 23.37% 1.05[0.16,6.74]
Subtotal (95% CI) 402 270 100% 2.41[1.05,5.52]
Total events: 27 (Oxcarbazepine), 7 (Control)  
Heterogeneity: Tau2=0; Chi2=1.14, df=2(P=0.57); I2=0%  
Test for overall effect: Z=2.09(P=0.04)  
   
4.2.3 26 weeks  
Barcs 2000 61/521 1/173 100% 20.26[2.83,145.02]
Subtotal (95% CI) 521 173 100% 20.26[2.83,145.02]
Total events: 61 (Oxcarbazepine), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3(P=0)  
Test for subgroup differences: Chi2=4.96, df=1 (P=0.08), I2=59.65%  
Favours control 2000.005 100.1 1 Favours oxcarbazepine
 
 
Analysis 4.3.   Comparison 4 Oxcarbazepine vs. control (Subgroup
analysis - Duration of treatment), Outcome 3 Treatment withdrawal.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.3.1 8 weeks or less  
NCT00975715 9/48 1/51 16.24% 9.56[1.26,72.67]
Pina-Garza 2005 8/64 5/64 83.76% 1.6[0.55,4.63]
Subtotal (95% CI) 112 115 100% 2.89[1.19,7.06]
Total events: 17 (Oxcarbazepine), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=2.53, df=1(P=0.11); I2=60.47%  
Test for overall effect: Z=2.33(P=0.02)  
   
4.3.2 16 weeks  
French 2014 92/245 26/121 73.91% 1.75[1.2,2.55]
Glauser 2000 21/138 10/129 21.95% 1.96[0.96,4.01]
Kraiprab 2005 1/19 2/20 4.14% 0.53[0.05,5.34]
Subtotal (95% CI) 402 270 100% 1.74[1.26,2.42]
Total events: 114 (Oxcarbazepine), 38 (Control)  
Heterogeneity: Tau2=0; Chi2=1.13, df=2(P=0.57); I2=0%  
Test for overall effect: Z=3.32(P=0)  
   
Favours oxcarbazepine 1000.01 100.1 1 Favours control
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Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.3.3 26 weeks  
Barcs 2000 246/521 49/173 100% 1.67[1.29,2.15]
Subtotal (95% CI) 521 173 100% 1.67[1.29,2.15]
Total events: 246 (Oxcarbazepine), 49 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.95(P<0.0001)  
Test for subgroup differences: Chi2=1.36, df=1 (P=0.51), I2=0%  
Favours oxcarbazepine 1000.01 100.1 1 Favours control
 
 
Comparison 5.   Oxcarbazepine vs. control (Subgroup analysis - Experimental dose)





Statistical method Effect size
1 50% or greater reduction in
seizure frequency
3   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 600 mg/d 1 342 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [1.32, 3.33]
1.2 1200 mg/d 3 633 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [1.50, 2.52]
1.3 2400 mg/d 2 591 Risk Ratio (M-H, Fixed, 95% CI) 2.42 [1.85, 3.16]
2 Seizure freedom 3   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 600 mg 1 341 Risk Ratio (M-H, Fixed, 95% CI) 5.15 [0.61, 43.61]
2.2 1200 mg 3 628 Risk Ratio (M-H, Fixed, 95% CI) 3.71 [1.62, 8.46]
2.3 2400 mg 2 591 Risk Ratio (M-H, Fixed, 95% CI) 10.28 [4.16, 25.43]
3 Treatment withdrawal 3   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 600 mg 1 342 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.55, 1.15]
3.2 1200 mg 3 633 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.21, 1.95]
3.3 2400 mg 2 591 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [1.92, 2.94]
 
 
Analysis 5.1.   Comparison 5 Oxcarbazepine vs. control (Subgroup analysis -
Experimental dose), Outcome 1 50% or greater reduction in seizure frequency.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.1.1 600 mg/d  
Barcs 2000 45/169 22/173 100% 2.09[1.32,3.33]
Subtotal (95% CI) 169 173 100% 2.09[1.32,3.33]
Favours control 50.2 20.5 1 Favours oxcarbazepine
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Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 45 (Oxcarbazepine), 22 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.12(P=0)  
   
5.1.2 1200 mg/d  
Barcs 2000 73/178 22/173 34.73% 3.22[2.1,4.95]
French 2014 44/122 34/121 53.14% 1.28[0.89,1.86]
Kraiprab 2005 9/19 8/20 12.13% 1.18[0.58,2.42]
Subtotal (95% CI) 319 314 100% 1.95[1.5,2.52]
Total events: 126 (Oxcarbazepine), 64 (Control)  
Heterogeneity: Tau2=0; Chi2=12.05, df=2(P=0); I2=83.4%  
Test for overall effect: Z=5.05(P<0.0001)  
   
5.1.3 2400 mg/d  
Barcs 2000 87/174 22/173 39.16% 3.93[2.59,5.97]
French 2014 50/123 34/121 60.84% 1.45[1.01,2.07]
Subtotal (95% CI) 297 294 100% 2.42[1.85,3.16]
Total events: 137 (Oxcarbazepine), 56 (Control)  
Heterogeneity: Tau2=0; Chi2=13.2, df=1(P=0); I2=92.43%  
Test for overall effect: Z=6.48(P<0.0001)  
Favours control 50.2 20.5 1 Favours oxcarbazepine
 
 
Analysis 5.2.   Comparison 5 Oxcarbazepine vs. control (Subgroup
analysis - Experimental dose), Outcome 2 Seizure freedom.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.2.1 600 mg  
Barcs 2000 5/168 1/173 100% 5.15[0.61,43.61]
Subtotal (95% CI) 168 173 100% 5.15[0.61,43.61]
Total events: 5 (Oxcarbazepine), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
   
5.2.2 1200 mg  
Barcs 2000 18/177 1/173 14.51% 17.59[2.37,130.35]
French 2014 6/122 4/121 57.62% 1.49[0.43,5.14]
Kraiprab 2005 2/17 2/18 27.87% 1.06[0.17,6.7]
Subtotal (95% CI) 316 312 100% 3.71[1.62,8.46]
Total events: 26 (Oxcarbazepine), 7 (Control)  
Heterogeneity: Tau2=0; Chi2=6.18, df=2(P=0.05); I2=67.62%  
Test for overall effect: Z=3.11(P=0)  
   
5.2.3 2400 mg  
Barcs 2000 38/174 1/173 19.92% 37.78[5.25,272.12]
French 2014 14/123 4/121 80.08% 3.44[1.17,10.16]
Subtotal (95% CI) 297 294 100% 10.28[4.16,25.43]
Total events: 52 (Oxcarbazepine), 5 (Control)  
Heterogeneity: Tau2=0; Chi2=5.59, df=1(P=0.02); I2=82.12%  
Favours control 10000.001 100.1 1 Favours oxcarbazepine
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Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=5.04(P<0.0001)  
Favours control 10000.001 100.1 1 Favours oxcarbazepine
 
 
Analysis 5.3.   Comparison 5 Oxcarbazepine vs. control (Subgroup
analysis - Experimental dose), Outcome 3 Treatment withdrawal.
Study or subgroup Oxcarbazepine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.3.1 600 mg  
Barcs 2000 38/169 49/173 100% 0.79[0.55,1.15]
Subtotal (95% CI) 169 173 100% 0.79[0.55,1.15]
Total events: 38 (Oxcarbazepine), 49 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
   
5.3.2 1200 mg  
Barcs 2000 80/178 49/173 63.92% 1.59[1.19,2.12]
French 2014 40/122 26/121 33.58% 1.53[1,2.33]
Kraiprab 2005 1/19 2/20 2.51% 0.53[0.05,5.34]
Subtotal (95% CI) 319 314 100% 1.54[1.21,1.95]
Total events: 121 (Oxcarbazepine), 77 (Control)  
Heterogeneity: Tau2=0; Chi2=0.87, df=2(P=0.65); I2=0%  
Test for overall effect: Z=3.57(P=0)  
   
5.3.3 2400 mg  
Barcs 2000 128/174 49/173 65.21% 2.6[2.02,3.35]
French 2014 52/123 26/121 34.79% 1.97[1.32,2.93]
Subtotal (95% CI) 297 294 100% 2.38[1.92,2.94]
Total events: 180 (Oxcarbazepine), 75 (Control)  
Heterogeneity: Tau2=0; Chi2=1.34, df=1(P=0.25); I2=25.11%  
Test for overall effect: Z=7.95(P<0.0001)  
Favours oxcarbazepine 200.05 50.2 1 Favours control
 
 
A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. actinium or barzepin or carbox or deprectal or "gp 47680" or lonazet or ocbz or oxalepsy or oxcarbamazepin* or oxcarbazepin* or oxetol
or oxpin or oxrate or "oxtellar xr" or oxypine or pharozepine or prolepsi or timox or trexapin or trileptal or trileptin AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsies, Partial EXPLODE ALL AND CENTRAL:TARGET
3. ((partial or focal) and (seizure* or epilep*)):AB,KW,MC,MH,TI AND CENTRAL:TARGET
4. #2 OR #3 AND CENTRAL:TARGET
5. #1 AND #4
6. (monotherap* NOT (adjunct* OR "add-on" OR "add on" OR adjuvant* OR combination* OR polytherap*)):TI AND CENTRAL:TARGET
#5 NOT #6
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Appendix 2. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. (actinium or barzepin or carbox or deprectal or "gp 47680" or lonazet or ocbz or oxalepsy or oxcarbamazepin$ or oxcarbazepin$ or oxetol
or oxpin or oxrate or "oxtellar xr" or oxypine or pharozepine or prolepsi or timox or trexapin or trileptal or trileptin).tw.
2. exp Epilepsies, Partial/
3. ((partial or focal) and (seizure$ or epilep$)).tw.
4. 2 or 3
5. 1 and 4
6. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$ or polytherap$)).ti.
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 7 and 13
15. remove duplicates from 14
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsies, Partial | Oxcarbazepine
Appendix 4. ICTRP search strategy
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have reported the proportion of participants who experienced each individual adverse eIect as risk ratios (RR) with 99% confidence
intervals (CI) rather than as RR with 95% CI, as specified in the review protocol, to compensate for multiple outcome testing.
We were unable to conduct a subgroup analysis stratified by the number of concomitant AEDs because the studies included in the review
did not report outcome data stratified by number of concomitant AEDs.
The term 'partial' has been replaced by 'focal', in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (ScheIer 2017).
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